<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2d1 20170631//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="article" dtd-version="1.2d1" specific-use="production" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">BIORXIV</journal-id>
<journal-title-group>
<journal-title>bioRxiv</journal-title>
<abbrev-journal-title abbrev-type="publisher">bioRxiv</abbrev-journal-title>
</journal-title-group>
<publisher>
<publisher-name>Cold Spring Harbor Laboratory</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1101/383075</article-id>
<article-version>1.1</article-version>
<article-categories>
<subj-group subj-group-type="author-type">
<subject>Regular Article</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>New Results</subject>
</subj-group>
<subj-group subj-group-type="hwp-journal-coll">
<subject>Microbiology</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>HIV-1 evasion of restriction factors: cyclophilin A and cell fusion provide a helping hand</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Owen</surname>
<given-names>Henry</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="corresp" rid="cor1">&#x002A;</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Vaughan-Jackson</surname>
<given-names>Alun</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="corresp" rid="cor1">&#x002A;</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nussbaum</surname>
<given-names>Lea</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vowles</surname>
<given-names>Jane</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>James</surname>
<given-names>William</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2630-0442</contrib-id>
<name>
<surname>Moore</surname>
<given-names>M.D.</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="author-notes" rid="n1">&#x0023;</xref>
</contrib>
<aff id="a1"><label>1</label><institution>Sir William Dunn School of Pathology, University of Oxford</institution>, South Parks Road, OX1 3RE</aff>
</contrib-group>
<author-notes>
<fn id="n1" fn-type="equal"><label>&#x002A;</label><p>Authors contributed equally.</p></fn>
<corresp id="cor1"><label>&#x0023;</label>Corresponding author. email: <email>Kenny.moore@medsci.ox.ac.uk</email></corresp>
</author-notes>
<pub-date pub-type="epub"><year>2018</year></pub-date>
<elocation-id>383075</elocation-id>
<history>
<date date-type="received">
<day>01</day>
<month>8</month>
<year>2018</year>
</date>
<date date-type="rev-recd">
<day>01</day>
<month>8</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>02</day>
<month>8</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>&#x00A9; 2018, Posted by Cold Spring Harbor Laboratory</copyright-statement>
<copyright-year>2018</copyright-year>
<license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link></license-p></license>
</permissions>
<self-uri xlink:href="383075.pdf" content-type="pdf" xlink:role="full-text"/>
<abstract>
<title>Abstract</title>
<p>Retroviral restriction factors are important regulators of viral infection, targeting vulnerable steps of the virus lifecycle; steps that are also targeted by antiviral drugs. It has become clear that the route of cellular infection can alter the sensitivity of HIV-1 to these agents. Using CRISPR-Cas9 edited pluripotent stem cell-derived macrophages, we have explored the potential of a modified restriction factor (human TRIMCyp) to inhibit HIV-1 replication in both cell free and cell-cell infection models. We show that the expression of TRIMCyp from the endogenous TRIM5&#x03B1; locus potently restricts infection by cell-free HIV-1. Our results also show the importance of the human cyclophilin A-HIV-1 capsid interaction for viral escape from restriction by native human TRIM5&#x03B1;, highlighting the evolutionary interplay between virus and this host restriction factor. However, when co-cultured with infected T cells, stem cell-derived macrophages are primarily infected by fusion between the cells. We have termed infected cells that result from these fusions heterocytia, and show that their formation overcomes multiple restriction factors and the reverse transcriptase inhibitor AZT.</p>
<sec>
<title>Importance</title>
<p>As sentinels of the immune system, macrophages are relatively resistant to infection by pathogens such as HIV-1. However, infected macrophages are found in infected patients and they play key roles in the pathogenesis of the disease as well as being a component of the viral reservoir that must be targeted before treatment can become cure. In this article, we show that some of the mechanisms by which macrophages restrict HIV-1 can be overcome through a recently described cell-cell interaction leading to cell-cell fusion. We also highlight an evolutionary battle between virus and host and show how the virus has co-opted a host protein to protect it from destruction by an antiviral mechanism. These two key findings suggest potential novel treatment strategies that may reduce the viral reservoir and help our natural defences take back control from the virus.</p>
</sec>
</abstract>
<counts>
<page-count count="38"/>
</counts>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Tissue resident macrophages are important for homeostasis, development and protection from invading pathogens (<xref ref-type="bibr" rid="c1">1</xref>). Their role against pathogens includes detection of pathogen-associated molecular patterns (PAMPs) by their numerous pattern recognition receptors (PRRs), inactivation of the pathogen, innate signalling via interferon to bolster the defences of surrounding cells, and antigen presentation to initiate an adaptive immune response. However, being at the first line of defence also makes subversion of macrophages an evolutionarily successful strategy for pathogens. As expressers of both CD4 and CCR5, macrophages stand alongside T cells as a natural host cell for HIV-1, and as a self-renewing population of tissue resident cells they also constitute a long-lived, inaccessible reservoir of virus that hampers viral clearance strategies (<xref ref-type="bibr" rid="c2">2</xref>). Consistent with their immune role, macrophages have several antiviral mechanisms to prevent infection by retroviruses such as HIV-1, namely the constitutive expression of retroviral restriction factors, e.g. TRIM5&#x03B1; and SAMHD1 (<xref ref-type="bibr" rid="c3">3</xref>).</p>
<p>TRIM5&#x03B1; binds to the viral capsid lattice of an incoming, retroviral core and results in early uncoating, proteasomal degradation of the viral capsid, and ultimately inhibition of reverse transcription; however human TRIM5&#x03B1; is inactive against HIV-1 (<xref ref-type="bibr" rid="c4">4</xref>). TRIM5&#x03B1; can be saturated by large doses of virus e.g. during viral dissemination via virological synapses, and can also be circumvented by alterations in the viral capsid gene that prevent TRIM5&#x03B1; binding (<xref ref-type="bibr" rid="c5">5</xref>, <xref ref-type="bibr" rid="c6">6</xref>). The compatibility between the viral capsid sequence and the host species TRIM5 locus is a major determinant of successful infection. In fact, converting a single amino acid to the equivalent in rhesus macaque TRIM5&#x03B1; is sufficient to enable human TRIM5&#x03B1; to restrict HIV-1 (<xref ref-type="bibr" rid="c7">7</xref>). The same region of capsid that determines the sensitivity of HIV-1 to TRIM5&#x03B1; is also the binding site for the host peptidyl prolyl isomerase enzyme cyclophilin A (CypA) (<xref ref-type="bibr" rid="c8">8</xref>). Binding of CypA to an incoming HIV-1 capsid prevents detection of reverse transcription products by macrophages, and the subsequent production of IFN, but conversely binding of CypA aids restriction by TRIM5 of some monkey species (<xref ref-type="bibr" rid="c9">9</xref>). This interaction site has been the focus of an evolutionary arms race between the TRIM5 locus and the simian relatives of HIV-1. In several monkey species (e.g. Rhesus macaques and Owl monkeys) multiple retrotransposition events resulted in CypA being inserted into the TRIM5 locus, producing a novel antiviral protein, TRIMCyp (<xref ref-type="bibr" rid="c10">10</xref>, <xref ref-type="bibr" rid="c11">11</xref>). Although TRIMCyp does not contain the usual PRYSPRY domain for viral binding, it uses the CypA domain to bind the capsid of sensitive viruses. The species-specific activity of TRIM5 and TRIMCyp suggest that they act as cross-species barriers to retrovirus infection (<xref ref-type="bibr" rid="c12">12</xref>, <xref ref-type="bibr" rid="c13">13</xref>), and that in consequence, the TRIM5 locus has great potential to act as a target for gene therapy. To that end, it has been shown that overexpression of macaque TRIM5 variants or TRIMCyp in human cells results in protection from HIV-1 infection (<xref ref-type="bibr" rid="c14">14</xref>, <xref ref-type="bibr" rid="c15">15</xref>). However, these approaches fail to take account of the role of endogenous TRIM5&#x03B1; as both a target and signaller of the IFN system (<xref ref-type="bibr" rid="c16">16</xref>), nor any potentially adverse consequences of overexpression of this potent antiviral element.</p>
<p>The other major restriction factor expressed by macrophages, SAMHD1, is a deoxynucleotide triphosphohydrolase enzyme (<xref ref-type="bibr" rid="c17">17</xref>). The activity of SAMHD1, conversion of dNTPs into deoxynucleosides (dNs), is essential to maintain balanced levels of dNTPs within cells, which is required for genome stability in dividing cells, and is used to reduce the availability of dNTPs to invading pathogens such as HIV and <italic>Leishmania</italic> in non-dividing cells (<xref ref-type="bibr" rid="c18">18</xref>-<xref ref-type="bibr" rid="c20">20</xref>). In activated T cells, SAMHD1 is both expressed poorly and inactivated by phosphorylation, thus it is unable to inhibit HIV-1 infection (<xref ref-type="bibr" rid="c21">21</xref>-<xref ref-type="bibr" rid="c23">23</xref>). In contrast, in terminally differentiated macrophages, SAMHD1 is expressed at high levels, is dephosphorylated, and reduces the levels of dNTPs to below the level required by the viral RT enzyme for efficient reverse transcription (<xref ref-type="bibr" rid="c19">19</xref>). Although HIV-1 has evolved to be able to replicate, albeit inefficiently, under these conditions, the virus has not evolved a specific counter measure such as VPx of SIV and HIV-2 that targets SAMHD1 for degradation (<xref ref-type="bibr" rid="c24">24</xref>), implying that HIV-1 infection is macrophage independent or that the virus has evolved a novel way of bypassing this restriction.</p>
<p>In this report, we use CRISPR/Cas9 to alter the restriction factors TRIM5&#x03B1; and SAMHD1 in order to investigate their impact on the infection of macrophages by HIV-1. By investigating both cell-free and cell-associated infection models we confirm the potency of these factors, but also highlight cell fusion as a mechanism by which they can both be efficiently overcome within tissue macrophages. For this work, we used pluripotent stem cell-derived macrophages (pMac) as a model system for tissue macrophages, as they are genetically tractable at the stem cell stage, karyotypically normal and terminally differentiated, as well as being ontologically, phenotypically and transcriptomically similar to authentic tissue macrophages (<xref ref-type="bibr" rid="c25">25</xref>, <xref ref-type="bibr" rid="c26">26</xref>), features not associated with cancerous cell lines or blood monocyte-derived macrophages.</p>
</sec>
<sec id="s2">
<title>Results</title>
<sec id="s2a">
<title>Endogenous human TRIMCyp Inhibits HIV-1 Infection</title>
<p>To measure the impact of TRIMCyp in human cells expressed at levels comparable with endogenous TRIM5&#x03B1;, we generated a pluripotent stem cell line containing a knock-in of human CypA into exon 8 of TRIM5&#x03B1; using a double nicking CRISPR-Cas9 approach (<xref ref-type="fig" rid="fig1">Fig 1A</xref>) (<xref ref-type="bibr" rid="c27">27</xref>). A single clone was identified carrying the CypA insertion in both alleles of TRIM5, as demonstrated by the single peaks of the sequencing trace (<xref ref-type="fig" rid="fig1">Fig 1B</xref>) that correspond to the fusion of TRIM5 with CypA at Serine 322 of TRIM5 (<xref ref-type="bibr" rid="c28">28</xref>). To observe the effect of human TRIMCyp on HIV-1 infection, the pluripotent stem cells and their differentiated macrophage progeny (pMac) (<xref ref-type="bibr" rid="c29">29</xref>) were exposed to increasing doses of a single-cycle GFP-expressing reporter virus, pseudotyped with VSV-G.</p>
<fig id="fig1" position="float" orientation="portrait" fig-type="figure">
<label>Figure 1</label>
<caption><p>Human TRIMCyp and TRIM5&#x03B1; inhibit HIV-1 of macrophages but are differentially affected by CypA. (A) The TRIM5 locus of a pluripotent stem cell line was targeted by CRISPR-Cas9 nickase at two sites (black arrow) within exon 8 to initiate homologous recombination with a plasmid donor template containing human CypA (hashed box). TRIM5 was also targeted with wildtype CRISPR-Cas9 targeting exon 2 (grey arrow) to produce a knockout phenotype. (B) Sequence trace of the TRIM5 locus at the insertion site of CypA in the identified double knock-in single cell clone. Infection of stem cells (C) and pMacs (D) from an unmodified clone (TRIM5&#x03B1;) and the genetically modified clone (TRIMCyp) with VSV-G-pseudotyped lentiviral vectors, in the presence of 5 &#x03BC;M CsA or DMSO, were quantified by flow cytometry for the reporter eGFP protein. Area under the curve (AUC) analysis of the lower 6 values of one representative serial dilution performed twice (C) or lower 4 values of four (D) independent serial dilutions are shown &#x002B;/- SEM (&#x002A;p&#x003C;0.05, &#x002A;&#x002A;&#x002A;&#x003C;0.001, &#x002A;&#x002A;&#x002A;&#x002A;p&#x003C;0.0001 from a 2-way ANOVA with Turkey&#x2019;s multiple comparisons test. (E) Infection results (mean &#x002B;/- SEM) for three different vector constructs all pseudotyped with JRFL envelope, normalized to the infectivity of each vector in DMSO treated wildtype pMacs (TRIM5&#x03B1;) (&#x002A;&#x002A;&#x002A;p&#x003C;0.001, &#x002A;&#x002A;&#x002A;&#x002A;p&#x003C;0.0001, for one-sample t-test to hypothetical value of 100, and &#x002A;p&#x003C;0.05 for t test). (F) Infectivity of pMacs to replication competent NL-LucR.T2A measured at day 7 post infection in 3&#x2013;4 independent experiments, plotted as mean &#x002B;/- standard deviation (&#x002A;&#x002A;&#x002A;p&#x003C;0.001, &#x002A;&#x002A;&#x002A;&#x002A;p&#x003C;0.0001 for one-sample t-test to hypothetical value of 100). Inset, a representative growth curve performed in quadruplicate over 5 days showing infection as relative light units (RLU) of luciferase. (G) Serial dilutions of VSV-G pseudotyped eGFP-reporter vector or (H) a P90A capsid mutant vector on pMacs from two wildtype clones (TRIM5&#x03B1; &#x002B;/&#x002B;) and two knockout clones (TRIM5&#x03B1; -/-) in the presence of 5 &#x03BC;M CsA or DMSO. The mean &#x002B;/- SEM of the infectivity, measured as multiplicity of infection (MOI) at each dilution from three independent experiments are shown.</p></caption>
<graphic xlink:href="383075_fig1.tif"/>
</fig>
<p>Infectivity in both stem cells and pMacs was reduced by conversion of TRIM5&#x03B1; to TRIMCyp (<xref ref-type="fig" rid="fig1">Fig 1C&#x002B;D</xref>, and FigS1A&#x002B;S2A). As TRIMCyp is inserted into the TRIM5 locus it can be considered a marker of TRIM5 expression in wild-type cells, thus reduced infectivity of gene-edited stem cells indicates that TRIM5&#x03B1; is normally expressed in pluripotent stem cells, potentially as a mechanism to prevent endogenous and exogenous retroviral infections of the embryo (<xref ref-type="bibr" rid="c30">30</xref>). In pMacs, TRIMCyp has a more dramatic impact on infectivity than in stem cells, reducing infection by 10-fold at most viral concentrations (Fig S2A). At higher concentrations of virus (shown in Fig S2A) it is possible to observe the well-established saturation of TRIM-based restriction, such as rhesus TRIM5&#x03B1; and owl monkey TRIMCyp (<xref ref-type="bibr" rid="c31">31</xref>). To demonstrate that the reduction in infection, seen in <xref ref-type="fig" rid="fig1">Fig 1C&#x002B;D</xref> and Fig S1A&#x002B;2A, was due to the modification at the TRIM5&#x03B1; locus and not to any off-target effect, the cells were treated with CsA during infection. CsA prevents CypA from binding the viral capsid and is known to rescue HIV-1 infection in TRIMCyp expressing cells. CsA has also been shown to reduce HIV-1 infectivity in human cells by an incompletely understood mechanism that has been linked to HIV-1 genome detection by cellular DNA detection pathways (<xref ref-type="bibr" rid="c9">9</xref>). In agreement with these data, our wild-type cells were more resistant to infection after treatment with CsA (<xref ref-type="fig" rid="fig1">Fig 1C&#x002B;D</xref>, Fig S1B&#x002B;S2B), whereas treatment of the gene edited stem cells and pMacs with CsA significantly inhibited restriction of HIV-1 by TRIMCyp (<xref ref-type="fig" rid="fig1">Fig 1C&#x002B;D</xref>, Fig S1C&#x002B;S2C).</p>
</sec>
<sec id="s2b">
<title>Human cyclophilin A protects HIV-1 from human TRIM5&#x03B1;</title>
<p>Other than overall size of effect, a major difference that is observed between the pluripotent stem cell progenitors and the differentiated pMacs, is a disparity between the unmodified and modified cells when both are treated with CsA (<xref ref-type="fig" rid="fig1">Fig 1C&#x002B;D</xref>). If one compares the results of wild-type macrophages expressing human TRIM5&#x03B1; with those of CsA-treated TRIMCyp-expressing cells (which express CsA-inactivated TRIMCyp, but no human TRIM5&#x03B1;) it would appear that TRIM5&#x03B1; has little or no activity against HIV-1 (Fig S1D&#x002B;S2D), confirming previously published data (<xref ref-type="bibr" rid="c32">32</xref>). However, the comparison of HIV-1-infection in the isogenic TRIM5&#x03B1; and TRIMCyp macrophages both in the presence of CsA, reveals a residual antiviral effect of TRIM5&#x03B1;. If human TRIM5&#x03B1; did not bind HIV-1, and CsA prevented TRIMCyp from binding, then in the presence of CsA both cells should have the same infectivity to HIV-1. However, as can be seen in <xref ref-type="fig" rid="fig1">Fig 1D</xref> and Fig S2E, TRIM5&#x03B1;-expressing pMacs treated with CsA are more resistant to HIV-1 than CsA-treated TRIMCyp-expressing pMacs, suggesting an interaction of human TRIM5&#x03B1; with the viral core when CypA binding is prevented. We hypothesise that HIV-1 has evolved to use CypA, to alter its conformation, as an evasion strategy to escape TRIM5&#x03B1; restriction. However, as stem cells did not show this phenotype (<xref ref-type="fig" rid="fig1">Fig 1C</xref> and Fig S1E) the impact of TRIM5&#x03B1; on CypA-deficient viruses appears to be cell-type dependent, as has recently been shown for TRIM5&#x03B1; function in Langerhans cells (<xref ref-type="bibr" rid="c33">33</xref>), possibly due to reduced effectiveness of downstream effectors in stem cells (<xref ref-type="bibr" rid="c34">34</xref>).</p>
<p>As the infection results were obtained using an exogenous reporter (eGFP) virus pseudotyped with VSV-G, an envelope that has been previously been shown to alter susceptibility to TRIM5&#x03B1; restriction (<xref ref-type="bibr" rid="c33">33</xref>), we performed the same infection experiments in pMacs using three different vectors that were pseudotyped with JRFL, a cognate macrophage-tropic HIV-1 envelope protein. As the different vectors had different reporter genes (eGFP or luciferase) the results were normalized to the infectivity of wild-type TRIM5&#x03B1; expressing cells. The results confirm those of the VSV-G pseudotyped vectors, with a 10-fold reduction in infectivity in both CsA-treated wild-type cells and in TRIMCyp-expressing cells, but a recovery of infection with CsA treatment of TRIMCyp-expressing cells over that of CsA-treated wild-type cells (<xref ref-type="fig" rid="fig1">Fig 1E</xref>).</p>
<p>To observe the impact of TRIMCyp in a more physiological setting, pMacs were exposed to wild-type replication-competent HIV-1 with a luciferase reporter expressed in the Nef open reading frame (NL-LucR.T2A). Tracking the infection over a 5-day period shows a robust growth of HIV-1 in TRIM5&#x03B1;-expressing cells, but not in TRIMCyp-expressing cells (<xref ref-type="fig" rid="fig1">Fig 1F</xref>, inset). Although CsA could inhibit replication in TRIM5&#x03B1;-expressing cells, it was not able to significantly alter infectivity of TRIMCyp expressing cells (<xref ref-type="fig" rid="fig1">Fig 1F</xref>), possibly due to the multifaceted way CypA is employed by the virus and, therefore, multiple stages of the virus lifecycle that could be affected by CsA (<xref ref-type="bibr" rid="c16">16</xref>, <xref ref-type="bibr" rid="c35">35</xref>).</p>
<p>To directly investigate the hypothesis that CypA alters the susceptibility of HIV-1 to human TRIM5&#x03B1; restriction, we generated pMacs knocked out for human TRIM5&#x03B1; using CRISPR/Cas9 (<xref ref-type="fig" rid="fig1">Fig 1A</xref>). Exposure of these cells to an HIV-1-based vector clearly confirms previous data showing a lack of robust restriction of HIV-1 by endogenous human TRIM5&#x03B1; (<xref ref-type="fig" rid="fig1">Fig 1G</xref>). However, in the presence of CsA the loss of infectivity observed with wild-type cells is abrogated by removal of TRIM5&#x03B1; (<xref ref-type="fig" rid="fig1">Fig 1G</xref>), which genetically proves our hypothesis (Fig S2F). To confirm the role of CypA in protection of HIV-1 from TRIM5&#x03B1;, the cells were exposed to the same reporter vector but harbouring the P90A mutation in capsid that prevents CypA binding. In line with the published literature, the P90A mutant is not affected by cell treatment with CsA, but in agreement with our hypothesis, the P90A mutant is more infectious in TRIM5&#x03B1;-knockout pMacs compared with wild-type cells (<xref ref-type="fig" rid="fig1">Fig 1H</xref>).</p>
</sec>
<sec id="s2c">
<title>TRIMCyp is circumvented by cell fusion</title>
<p>As TRIM5&#x03B1; and TRIMCyp restriction can be overcome by saturation with incoming viral cores (<xref ref-type="bibr" rid="c31">31</xref>), and it is known that cell-to-cell transmission (e.g. via a virological synapse) can result in large quantities of viral material being transferred to the target cell (<xref ref-type="bibr" rid="c36">36</xref>, <xref ref-type="bibr" rid="c37">37</xref>), we set out to establish whether endogenous levels of TRIMCyp were sufficient to protect cells in the more physiological setting of cell-cell contact. To test this, we employed the same experimental set up that was used to demonstrate phagocytosis of infected T cells as a potential route for HIV-1 infection of macrophages (<xref ref-type="bibr" rid="c38">38</xref>), with some minor adjustments. As an initial experiment, NL-LucR.T2A infected Jurkat-R5 cells were co-cultured with wild-type or TRIMCyp macrophages for 6 hours and infection of the macrophages was assessed 7 days later (<xref ref-type="fig" rid="fig2">Fig 2A</xref>). In contrast to the data obtained by <xref ref-type="bibr" rid="c38">Baxter et al. 2014</xref>, we did not see a significant difference between infection levels in the presence or absence of the reverse transcriptase inhibitor AZT, even though in experiments using cell-free virus, AZT reduced infection of the macrophages (<xref ref-type="fig" rid="fig2">Fig 2B</xref>). To investigate the reverse transcriptase-independent results further, and to show that the results were not dependent on the genotype of the induced pluripotent stem cell donor, the experiment was repeated using pMacs from three independent donors, using both AZT and the fusion inhibitor, T20 or enfuvirtide (<xref ref-type="bibr" rid="c39">39</xref>). Once again, the level of infection was unaffected by AZT, however T20 reduced the level of infection more than 10-fold (<xref ref-type="fig" rid="fig2">Fig 2C</xref>), indicating that HIV-1 envelope-driven fusion of the cells was the major cause of the observed infection, a process that appears to be unaffected by TRIMCyp expression.</p>
<fig id="fig2" position="float" orientation="portrait" fig-type="figure">
<label>Figure 2</label>
<caption><p>Cell-cell infection of pMacs overcomes TRIMCyp. (A) Macrophages co-cultured with NL-LucR.T2A-infected Jurkat-R5 cells for 6 hours were measured for infection after 7 days, during which etoposide treatment removed residual T cells. Co-cultures were performed in the presence or absence of AZT and are presented as the level of luciferase normalized to the wildtype (TRIM5&#x03B1;) pMacs in the absence of AZT. Results are plotted as mean &#x002B;/- standard deviation of 3 independent experiments. (B) Effect of AZT on cell free infection of pMacs measured 7 days post infection. Results are plotted as mean &#x002B;/- standard deviation of 3 independent experiments normalized to the no drug control (&#x002A;p&#x003C;0.05, t-test). (C) Effect of anti-HIV drugs AZT and T20 on pMac infection in the cell-cell infection model, co-culturing the cells for 16 hours followed by 4 days etoposide treatment prior to luciferase measurement. Results (raw relative light units or RLU) show the mean &#x002B;/- standard deviation from three different donor (lines 856&#x2013;03&#x2013;04, OX1.19 and HUES2) pMacs (&#x002A;&#x002A;&#x002A;p&#x003C;0.001, t-test). (D) Cell-cell infection of pMacs from NL-LucR.T2A infected PBMC-derived CD4&#x002B; T cells is enhanced by inhibiting IFN signalling using the JAK1/2 inhibitor Ruxolitinib (Rux). Results are depicted as the mean &#x002B;/- standard deviation from three different donors normalized to untreated wildtype TRIM5&#x03B1;-expressing macrophages (&#x002A;p&#x003C;0.05, t-test with Holm-Sidak method for correction for multiple comparisons). (E) Results from (D) were normalized to the level of infection of each macrophage population in the presence of AZT (&#x002A;p&#x003C;0.05, one-sample t-test to hypothetical value of 100, and &#x002A;&#x002A;p&#x003C;0.01, t-test). (F) Supernatants from (D) were assayed by Luminex for a variety of cytokines/chemokines, a subset of which are shown. The results are plotted individually with mean &#x002B;/- standard deviation indicated (&#x002A;&#x002A;p&#x003C;0.01, Kruskal-Wallis test, &#x002A;p&#x003C;0.05, ANOVA with Sidak&#x2019;s multiple comparison correction) and the limit of detection is indicated by the hashed area. (G) Representative micrographs of wildtype macrophages on day 7 post coculture with donor derived infected T cells, with black arrows depicting giant syncytial cells.</p></caption>
<graphic xlink:href="383075_fig2.tif"/>
</fig>
<p>To test the hypothesis that T cell-macrophage fusion bypasses TRIM-based restriction in a more physiological setting, PBMC-derived CD4&#x002B; T cells from three independent donors were infected with NL-LucR.T2A and co-cultured with wild-type or TRIMCyp-expressing pMacs in the presence of AZT, T20 and the IFN-signalling inhibitor Ruxolitinib (Rux). Again, the levels of infection were not significantly altered by the presence of AZT, whereas T20 significantly reduced infection (<xref ref-type="fig" rid="fig2">Fig 2D</xref>). Additionally, preventing IFN signalling enhanced infection, particularly in the TRIM5&#x03B1; expressing cells (<xref ref-type="fig" rid="fig2">Fig 2D</xref>). By subtracting the background signal of fusion-induced infection (AZT control), it is possible to observe replication of HIV-1 during and/or after the co-culture (<xref ref-type="fig" rid="fig2">Fig 2E</xref>), which highlights the significant impact of TRIMCyp expression as well as IFN in this experimental setting. A Luminex<sup>&#x00AE;</sup> assay on the culture supernatants confirmed the release of IFN&#x03B1; in untreated conditions and an elevation of the proinflammatory cytokine IL-1&#x03B2;, without any impact on the other cytokines/chemokines assayed, e.g. the chemoattractant MCP-1 (<xref ref-type="fig" rid="fig2">Fig 2F</xref>).</p>
<p>Upon observing the co-cultures of macrophages and PBMC-derived T cells by light microscopy it became apparent that a major difference between the treatments was the absence of giant syncytial cells in the T20 treated cells (<xref ref-type="fig" rid="fig2">Fig. 2G</xref>). It has been known for many years that HIV-1-directed fusion between macrophages can result in giant multinucleated syncytia (<xref ref-type="bibr" rid="c40">40</xref>, <xref ref-type="bibr" rid="c41">41</xref>). However, given that the majority of infection in the macrophages was independent of HIV-1 reverse transcription (AZT result in <xref ref-type="fig" rid="fig2">Fig. 2A&#x002B;D</xref>), we hypothesised that the major route of macrophage infection in our experimental setting was T cell-macrophage fusion. To address this, we performed live cell fluorescence microscopy on co-cultures of CellTracker<sup>&#x2122;</sup> Orange CMRA-stained pMacs with T cells infected by an eGFP-expressing replication-competent HIV-1. Within 30 minutes, fusion between T cells and macrophages was observed in the co-cultures, with the eGFP-tagged HIV-1 Gag protein being rapidly transferred from the T cell to the macrophage over a period of 5 minutes (<xref ref-type="fig" rid="fig3">Fig 3A</xref> and Video S1). This process resulted in macrophages harbouring an infected T cell-derived nucleus in the absence of reverse transcription. The destiny of each virally infected T cell was quantified over a 2-hour period post-co-culture (<xref ref-type="fig" rid="fig3">Fig 3B</xref>). The major events included both cell-cell fusion (rapid mixing of the cytoplasmic contents) and cell capture (attachment and colocalisation of a T cell within a macrophage, without cytoplasmic mixing, in a process consistent with phagocytosis of live cells, in Fig S3A, or apoptotic cells in Fig S3B (<xref ref-type="bibr" rid="c38">38</xref>). Additional events included rapid loss of GFP signal from the T cell in a process consistent with cell lysis (Fig S3C) and transfer of virus from the T cell to the macrophage in a process consistent with the formation of a virological synapse or plasma membrane transfer between immune cells (Fig S3D) (<xref ref-type="bibr" rid="c42">42</xref>, <xref ref-type="bibr" rid="c43">43</xref>). The only event that was modified by antiviral drug treatment was cell fusion by T20, demonstrating that the results for cell-cell infection (<xref ref-type="fig" rid="fig2">Fig 2A&#x002B;C&#x002B;D</xref>) were the outcome of the formation of a fusion of infected T cells with uninfected macrophages; the product of which we have termed heterocytia, to distinguish them from syncytia, derived from a single cell type, and heterokaryons, derived from genetically different parents.</p>
<fig id="fig3" position="float" orientation="portrait" fig-type="figure">
<label>Figure 3</label>
<caption><p>Heterocytium formation results in reverse-transcriptase independent macrophage infection. (A) Representative images of two HIV-1 eGFP-reporter virus infected Jurkat-R5 cells (green) fusing with stem cell-derived macrophages (red). (B) Quantification of cell fates of infected Jurkat-R5 T cells within the co-culture over a 2-hour period. The average number of events from 4 fields of view is also shown. (C) SAMHD1-knockout macrophages show elevated levels and kinetics of infection. The replication of NL-LucR.T2A virus in SAMHD1-knockout macrophages from three independent pMac factories performed in triplicate is shown as mean &#x002B;/- standard deviation and is compared to that of the parental isogenic wildtype (WT) macrophages. (D) Co-culture of NL-LucR.T2A infected Jurkat-R5 cells with an isogenic pair of macrophages, differing only in the loss of SAMHD1, shows that restriction by SAMHD1 is overcome by cell fusion. Infectivity of the macrophages, in the presence or absence of AZT and T20, was measured 5 days post co-culture with 4 days of etoposide treatment. Results (raw RLU values) are presented as the mean &#x002B;/- standard deviation of three independent co-culture experiments. (E) Ratio of phosphorylated to total SAMHD1 levels within the co-culture of pMacs and HIV-1 envelope-expressing CEM T cells. The mean &#x002B;/- standard deviation of 3&#x2013;5 experiments using two pMac donors are shown, with fusion being prevented by the inhibitors T20 or Tak779, or by use of CEM cells lacking the HIV-1 envelope (&#x002A;&#x002A;p&#x003C;0.01, t-test). (F) HIV-1 eGFP-reporter virus infected Jurkat-R5 cells (green), cultured with tRFP-expressing microglial precursors (pMGL, red), both stained with Hoechst 33342 to identify nuclei (blue), form heterocytia with classical giant cell morphology (white arrows) compared with macrophage heterocytia (pMac), in the presence of AZT but not T20.</p></caption>
<graphic xlink:href="383075_fig3.tif"/>
</fig>
</sec>
<sec id="s2d">
<title>Heterocytia formation overcomes SAMHD1 restriction</title>
<p>Given the ability of heterocytia formation to overcome potent TRIMCyp restriction and to result in infected macrophages without reverse transcription, we next investigated if the other major antiretroviral mechanism employed by macrophages, SAMHD1, was also circumvented. We have previously generated macrophages from pluripotent stem cells genetically ablated for the retroviral restriction factor SAMHD1 (<xref ref-type="bibr" rid="c44">44</xref>). SAMHD1 knockout macrophages show faster and more efficient infection by HIV-1 when exposed to NL-LucR.T2A virions (<xref ref-type="fig" rid="fig3">Fig 3C</xref>). However, when cocultured with NL-LucR.T2A -infected T cells, the isogenic pairs of macrophages, differing only by the presence of SAMHD1, show similar levels of infection (<xref ref-type="fig" rid="fig3">Fig 3D</xref>). This infection is unaffected by AZT, but reduced by T20, which demonstrates that cell fusion not only bypasses TRIM5&#x03B1;-mediated restriction but also SAMHD1 restriction, making it independent of the major retroviral restriction factors and, therefore, potentially the most efficient method of macrophage infection.</p>
<p>Given that in dividing cells SAMHD1 is inactivated by cyclin dependent kinase (CDK) phosphorylation at T592 we hypothesized that cell fusion would also alter the regulation of pMac SAMHD1. Within macrophages, SAMHD1 is generally unphosphorylated, and therefore active, whereas in T cell lines such as CEM cells it is not expressed. Therefore, upon fusion between the two cells, any detected increase in phosphorylated SAMHD1 would indicate an interaction between the cells&#x2019; proteomes. We co-cultured pMacs from three donors with a CEM cell line constitutively expressing the HIV envelope, for 24 hours before lysing the cells and probing for SAMHD1 phosphorylation by western blot. Quantification of the ratio of phosphorylated SAMHD1 to total SAMHD1 shows that the pMac SAMHD1 is inactivated by fusion with the T cell (<xref ref-type="fig" rid="fig3">Fig 3E</xref> and Fig S4E).</p>
</sec>
<sec id="s2e">
<title>Heterocytia formation occurs in stem cell-derived microglia</title>
<p>To investigate the potential of T cells to fuse with microglia in the brain and thereby generate giant cells, frequently observed in HIV encephalopathy, we employed our recently described and validated pluripotent stem cell model of microglia (<xref ref-type="bibr" rid="c26">26</xref>). Differentiating stem cell-derived macrophages in the presence of IL-34 results in microglial progenitor like cells (pMGL) that adopt highly ramified and mobile phenotypes characteristic of microglia in vivo. Addition of T cells infected with an eGFP-expressing replication competent reporter virus to tRFP-expressing pMGLs resulted in not only the heterocytia observed with pMacs, but also giant multinucleated cells with peripherally arranged nuclei that more closely resemble tissue giant cells, e.g. Langhans giant cells, HIV-associated giant cells of the lymphoid Waldeyer&#x2019;s ring, and HIV encephalitis associated multinucleated cells (<xref ref-type="fig" rid="fig3">Fig 3F</xref>) (<xref ref-type="bibr" rid="c40">40</xref>, <xref ref-type="bibr" rid="c41">41</xref>).</p>
</sec>
</sec>
<sec id="s3">
<title>Discussion</title>
<p>Macrophages are inherently resistant to HIV-1 infection due to low levels of the viral receptors CD4 and CCR5, high levels of active SAMHD1, and the ability to detect and respond to infections with a robust innate response. Nevertheless, they represent a natural target cell for HIV-1 <italic>in vivo</italic>, contributing to the viral reservoir (<xref ref-type="bibr" rid="c45">45</xref>), and are perhaps the most elusive targets for drug treatment, residing in difficult to reach regions such as the CNS, in the form of microglia (<xref ref-type="bibr" rid="c46">46</xref>). Most studies into HIV-1 infection of macrophages make use of either monocytic cell lines that have altered cell cycle control and loss of SAMHD1 activity, or blood monocyte-derived macrophages differentiated in vitro under various non-physiological conditions, e.g. high levels of FCS, which is known to alter SAMHD1 activity (<xref ref-type="bibr" rid="c47">47</xref>). Given the importance of SAMHD1 in repressing HIV-1 replication, neither of these cellular models is ideal. Moreover, in most tissues monocytes only invade and differentiate into macrophages under inflammatory conditions, so their role in HIV-1 transmission and subsequent pathogenesis is unclear. In contrast, tissue resident macrophages are present within all tissues at steady state, including within the mucosa at the site of infection and, in most tissues, are ontologically distinct from monocytes, being derived from Myb-independent erythro-myeloid progenitors (EMP) of the yolk sac and foetal liver during embryogenesis, not hematopoietic stem cells of the adult bone marrow (<xref ref-type="bibr" rid="c2">2</xref>). We have recently shown that pluripotent stem cell-derived macrophages differentiate via an EMP, in a Myb-independent manner (<xref ref-type="bibr" rid="c25">25</xref>). Thus, we feel that they are an excellent model of tissue resident macrophages such as microglia, and could help to define the molecular and cellular players during transmission at the mucosa and during neuropathology.</p>
<p>In this work we have used the stem cell-derived model of tissue macrophages to explore the role of TRIM5&#x03B1; on HIV-1 infection. Through genetic manipulation of the human TRIM5&#x03B1; locus to encode the anti-HIV-1 restriction factor TRIMCyp, we have shown that endogenous levels of this protein provide the cells with potent protection from HIV-1 replication. Using CsA to prevent the activity of the CypA component of TRIMCyp, we have also revealed an interesting feature of native human TRIM5&#x03B1; activity. It has long been established that human TRIM5&#x03B1; has little to no activity against HIV-1, however there has been confusion over the impact of CsA on this activity. Initial work suggested that CsA was able to enhance the activity of TRIM5&#x03B1; (<xref ref-type="bibr" rid="c48">48</xref>), however the same group and others subsequently presented data that conflicted with this concept (<xref ref-type="bibr" rid="c49">49</xref>-<xref ref-type="bibr" rid="c51">51</xref>). The current model of CsA action involves destabilization of the viral capsid through loss of CypA binding, resulting in early detection of nascent HIV-1 DNA by cGAS, IFN&#x03B1; production, and suboptimal integration site selection (<xref ref-type="bibr" rid="c52">52</xref>). The genetic data presented here shows that TRIM5&#x03B1; does inhibit HIV-1 under conditions in which viral cores lack CypA, either through treatment with CsA or the P90A mutation of Gag. As TRIM5&#x03B1; has been shown to destabilize cores in susceptible virions (<xref ref-type="bibr" rid="c53">53</xref>), we hypothesize that without CypA, TRIM5&#x03B1; binds the core, reducing its stability and resulting in detection of the viral DNA. This suggests that HIV-1 evolved to bind CypA as a direct countermeasure to the activity of human TRIM5&#x03B1;, with the added benefit of keeping the virus from detection by the innate immune response. This would suggest that CsA, or one of its non-immunosuppressive variants (<xref ref-type="bibr" rid="c54">54</xref>, <xref ref-type="bibr" rid="c55">55</xref>), could be used therapeutically to assist the antiviral effects of endogenous TRIM5&#x03B1;. However, previous attempts using CsA in HIV-1 patients have met with mixed success (<xref ref-type="bibr" rid="c56">56</xref>-<xref ref-type="bibr" rid="c58">58</xref>). Moreover, as we have identified heterocytium-formation as a potentially significant cell-cell infection pathway, even this approach to activate TRIM5&#x03B1; could be circumvented.</p>
<p>Although infection by cell-free HIV-1 can occur, cell-cell interactions have been shown to enhance transmission between cells. The virological synapse (<xref ref-type="bibr" rid="c43">43</xref>), tunnelling nanotubes (<xref ref-type="bibr" rid="c59">59</xref>) and phagocytosis of infected T cells (<xref ref-type="bibr" rid="c38">38</xref>) have all been observed to enable directed transmission of HIV-1 between cells. However, these all require reverse transcription, a weak link in the viral lifecycle that is targeted by multiple restriction factors (e.g. APOBEC3G/F, SAMHD1, TRIM5) and is a key drug target (e.g. NNRTIs and NRTIs). The data presented here show that cell fusion between T cells and macrophages is an efficient infection process, resulting in an infected heterocytium, that bypasses reverse transcription, thereby avoiding reverse transcription-targeting restriction factors and antiviral drugs.</p>
<p>Syncytium-formation is a fundamental property of mammalian development, being at the heart of trophoblast formation, osteoclast differentiation and muscle fiber generation. However, syncytia are also found in many pathological settings, e.g. Langhans giant cells, giant cells of granulomas and multinucleated giant cells of viral infection. From the perspective of HIV-1 infection, syncytium formation of <italic>in vitro</italic>-infected T cells has historically been linked to CXCR4-tropic viral strains that are also associated with more rapid disease progression (<xref ref-type="bibr" rid="c60">60</xref>).</p>
<p>Heterocytia have also been observed within <italic>ex vivo</italic> cultured T cell and dendritic cell co-cultures from tonsil lymph nodes from infected individuals (<xref ref-type="bibr" rid="c61">61</xref>). In vivo evidence for the existence of syncytia was for a long time limited to immunohistochemical identification of multinucleated giant cells within the CNS of HIV-associated encephalitis cases (<xref ref-type="bibr" rid="c62">62</xref>). More recent studies using humanized mouse models have highlighted a significant amount of small T cell-derived syncytia within the tight confines of lymphoid tissues (<xref ref-type="bibr" rid="c63">63</xref>). However, to date these HIV-1-induced syncytia have been reported solely from a phenomenological viewpoint, with little research into their pathophysiological consequences. HIV-1-driven T cell-macrophage fusion has also been previously observed (<xref ref-type="bibr" rid="c64">64</xref>, <xref ref-type="bibr" rid="c65">65</xref>), but as low frequency events under certain differentiation conditions that promote the fusogenic properties of macrophages. Our data corroborate this phenomenon and show that it is highly efficient in stem cell-derived macrophages, an authentic cell model of tissue resident macrophages. Such fusion events, <italic>in vivo</italic>, between short-lived infected T cells and long-lived self-renewing tissue macrophages could be of paramount importance in establishing (<xref ref-type="bibr" rid="c1">1</xref>) a beachhead at the site of infection, and (<xref ref-type="bibr" rid="c2">2</xref>) a viral reservoir in tissues such as the brain as infected T cells transit through the CNS and interact with microglia (<xref ref-type="bibr" rid="c66">66</xref>). Additionally, during cross-species transmission events such interspecies heterocytia would allow viral infections to overcome incompatibilities between the virus and innate restriction factors, e.g. TRIM5&#x03B1;. The presence of heterocytia <italic>in vivo</italic> would also provide an alternative explanation for the observation of rearranged TCR DNA within macrophage populations isolated from experimentally infected SIV rhesus macaques (<xref ref-type="bibr" rid="c67">67</xref>). Finally, although this study does not address the pathophysiology of these heterocytia during HIV-1 infection, the efficiency of their formation <italic>in vitro</italic> shown in this study, added to <italic>in vivo</italic> observations of syncytia, suggests that they might be a valuable target for treatment. Given that our data demonstrate that the formation of syncytia could be inhibited by the fusion inhibitor T20 and could potentially be limited by IFN&#x03B1;, it is possible that early treatment with these antiviral agents could prevent the neuropathological consequences of infection and reduce the macrophage viral reservoir.</p>
</sec>
<sec id="s4">
<title>Materials and Methods</title>
<sec id="s4a">
<title>Cell Culture</title>
<p>Cell culture reagents were sourced from Invitrogen unless otherwise stated. Wild-type human induced pluripotent cell lines SFC840&#x2013;03&#x2013;03 (<xref ref-type="bibr" rid="c26">26</xref>), SFC856&#x2013;03&#x2013;04 (<xref ref-type="bibr" rid="c26">26</xref>), OX1-19 (<xref ref-type="bibr" rid="c29">29</xref>) and AH016-3 Lenti&#x005F;IP&#x005F;RFP (<xref ref-type="bibr" rid="c26">26</xref>) and pluripotent stem cell line (HUES2) and its derivatives, have been characterised previously (<xref ref-type="bibr" rid="c44">44</xref>). The induced pluripotent stem cell lines were originally derived from healthy donors recruited through the Oxford Parkinson&#x2019;s Disease Centre having given signed informed consent (Ethics Committee that specifically approved this part of the study, National Health Service, Health Research Authority, NRES Committee South Central, Berkshire, UK, REC 10/H0505/71). All experiments were performed in accordance with UK guidelines and regulations and as set out in the REC. Stem cells were grown in mTeSR<sup>&#x2122;</sup>1 on Matrigel<sup>&#x00AE;</sup> (Corning)-coated tissue culture dishes, passaged using TrypLE<sup>&#x2122;</sup> and plated with the Rho-kinase inhibitor Y-27632 (10 &#x03BC;M; Abcam). Stem cells were differentiated into pMacs using an established macrophage protocol(<xref ref-type="bibr" rid="c29">29</xref>), and where necessary were cultured in microglia induction media as previously described (<xref ref-type="bibr" rid="c26">26</xref>). The CCR5-expressing T cell line, Jurkat-R5, was a kind gift from Prof. Q. Sattentau. The HIV-1 envelope-expressing CEM T cell line (CEM-HO-BaL) was engineered using a VSV-G-pseudotyped lentiviral vector co-expressing puromycin and HIV-1 BaL envelope, and a second generation vector (NL4.3R-E-HSA-T2A-Nef) to provide all accessory proteins required for BaL expression. Primary CD4 positive T cells were isolated from donor-derived peripheral blood mononuclear cells (obtained with written informed consent) using the MACS (Miltenyi) CD4&#x002B; T cell isolation kit according to the manufactures guidelines and were maintained in RPMI with 10&#x0025; foetal calf serum and 1&#x0025; pen/strep and activated using 1 &#x03BC;g/ml PMA and 10 units/ml IL-2 for 24 hrs, 3 days prior to infection with replication competent virus.</p>
</sec>
<sec id="s4b">
<title>Genome Engineering</title>
<p>TRIMCyp modification: The CRISPR-Cas9 plasmids used in this study were based on the dual guide RNA (gRNA) and Cas9<sup>D10A</sup>-expressing plasmid, pX335-U6-Chimeric&#x005F;BB-CBh-hSpCas9 (pX335), and its puromycin-resistance gene-expressing derivative, pX462(<xref ref-type="bibr" rid="c68">68</xref>) (gifts from Feng Zhang; Addgene plasmids &#x0023;42335 and &#x0023;48141). Cloning was performed as previous described(<xref ref-type="bibr" rid="c68">68</xref>) using oligonucleotides TRIM1f (CACCGCGAAACCACACGATAATATAT) and TRIM1r (AAACATATATTATCTGTGGTTTCGC) with BbsI digested pX335 to create pX335-Trim51, oligonucleotides TRIM3f (CACCGACAGCACATGAAATGTTGTT) and TRIM3r (AAACAACAACATTTCATGTGCTGTC) with pX462 to create pX462-TRIM3. The donor template was constructed from OX1.19 stem cell cDNA, amplifying three fragments: (<xref ref-type="bibr" rid="c1">1</xref>) the 5&#x2019; homology arm with primer TRIMcyp1f (TGGTACCGAGCTCGGATCCATGTCAAACACCCAGGAGC) and TRIMcyp1r (TGGGGTTGACAGAGCTCACTTGTCTCTTATCTTC), (<xref ref-type="bibr" rid="c2">2</xref>) Cyclophilin A with primer TRIMcyp2f (AGTGAGCTCTGTCAACCCCACCGTGTTC) and TRIMcyp2r (GAGCCCAGGATTATTCGAGTTGTCCACAGTC) and (<xref ref-type="bibr" rid="c3">3</xref>) the 3&#x2019; homologous arm with primer TRIMcyp3f (ACTCGAAT AAT CCTGGGCTCT CAAAGTATC) and TRIMcyp3r (TGGGCCCTCTAGATGCATGCACACTGCTGGTATATGGAGAG). The three fragments were assembled using the Gibson Assembly<sup>&#x00AE;</sup> mastermix (NEB), according to the manufacturer&#x2019;s guidelines, into XhoI and SpeI digested pCR2.1-TOPO (Invitrogen), to generate pTOPO-TRIMCyp.</p>
<p>The pluripotent stem cell line, SFC840&#x2013;03&#x2013;03, was Neon<sup>&#x00AE;</sup> (Invitrogen) transfected with pX335-TRIM1, pX462-TRIM3 and pTOPO-TRIMCyp, as previously (<xref ref-type="bibr" rid="c69">69</xref>). Twenty-four hours post-transfection cell were selected for 48 hours in 0.25 &#x03BC;g/ml puromycin. Once recovered the surviving cells were plated on mouse embryonic fibroblasts and single cell cloned, as previously (<xref ref-type="bibr" rid="c69">69</xref>). The correct genotype was identified by amplification of the TRIMCyp gene with primers CypAF (CATTGCTGACTGTGGACAACTC) and OutR2 (GCCATTTAAGTATGTTATTCACAG), and was shown to be a homozygous knock-in using primers TRIMsurF (CTGACAGATGTCCGACGCTACT) and TRIMsurR (CGATCAGGACAAATAATCACAGAGA), the product of which was Sanger sequenced using primer TRIMHRMr2 (ACACGTCTACCTCCCAGTAATGTTT)</p>
<p>TRIM5 Knockout: To knockout TRIM5 expression a lentiviral vector (pLentiCRISPRv2.0, gift from Feng Zhang, Addgene plasmid # 52961) was used. Oligos targeting exon 2 of TRIM5&#x03B1; (CACCGTTGATCATTGTGCACGCCA and AAACTGGCGTGCACAATGATCAAC) were annealed, phosphorylated and ligated into BsmBI digested vector as described (<xref ref-type="bibr" rid="c70">70</xref>). VSV-G pseudotyped vector was used to transduce SFC840&#x2013;03&#x2013;03 cells, which were subsequently selected with 1 &#x03BC;g/ml puromycin for 7 days before single cell cloning on mouse embryonic fibroblasts. Successful knockout clones were identified by Sanger sequencing of the PCR product using primers TRIM5seqF (GTGAAAGCCCTGAGGCATAA) and TRIM5seqR (CCTGCTGAAAGGGGTAATCA) followed by TIDE analysis (<xref ref-type="bibr" rid="c71">71</xref>). The two knockout clones used in this work were a homozygous out-of-frame mutant (11 base pair deletion and single base pair insertion) and a heterozygous double out-of-frame mutant (5 base pair deletion in one allele and 4 base pair deletion in the other).</p>
</sec>
<sec id="s4c">
<title>Lentiviral transduction and Transfection</title>
<p>Lentiviral vectors were generated by PEI-mediated transient transfection of 293T cells using pCMVdeltaR8.2 packaging vector for self-inactivating vectors and either pMD2.G for VSV-G pseudotyped vectors (gifts from Didier Trono; Addgene plasmids &#x0023;12263 and &#x0023;12259), or pJRFL for JRFL pseudotyped vectors. The vectors used included pHR&#x2019;SIN-cPPT-PGK-GIP (a derivative of pHR&#x2019;SIN-cPPT-EF1-GIP (<xref ref-type="bibr" rid="c69">69</xref>), pHIV-HIG (<xref ref-type="bibr" rid="c72">72</xref>), pNL4-3.Luc.R-E- (<xref ref-type="bibr" rid="c73">73</xref>, <xref ref-type="bibr" rid="c74">74</xref>), pNL4.3R-E- eGFPT2ANef (derived from pNL4-3.Luc.R-E-by replacing the luciferase gene with eGFP). Additionally, pNL4.3R-E-eGFPT2ANef was modified to incorporate the capsid mutant, P90A, using annealed oligos P90Afrd (CAGGGGCTATTGCACCAGGCCAGATGAGAGAACCAAGGGGAAGTGACATAGCAGGAACTA) and P90Arev (CTAGTAGTTCCTGCTATGTCACTTCCCCTTGGTTCTCTCATCTGGCCTGGTGCAATAGCCCCTGCATG).</p>
<p>To replace the fragment released by digestion with SphI and SpeI. Finally, pNL4.3R-E-eGFPT2ANef was modified to include the selectable heat stable antigen (HSA) gene from pHIV-HIG. Where required cells were pretreated with 5 &#x03BC;M CsA or equivalent percentage of DMSO 2 hours prior to infection with viral vectors. Stem cells and pMacs were plated 24 hours or 7 days, respectively, prior to infection in 96 well plates in 100 &#x03BC;l. Infection was carried out by replacing 50 &#x03BC;l of supernatant with 50 &#x03BC;l of three-fold serial dilutions of virus and incubation for 3 days prior to infectivity assay. Fluorescent viruses were quantified by flow cytometry (BD FACSCaliber) and luciferase viruses were quantified by One-Glo<sup>&#x2122;</sup> Luciferase assay (Promega) according to manufacturer&#x2019;s guidelines.</p>
</sec>
<sec id="s4d">
<title>Replication Competent Assays</title>
<p>The BaL envelope-expressing replication competent viruses either with the reporter renilla luciferase (NL-LucR.T2A (<xref ref-type="bibr" rid="c74">74</xref>) or eGFP (NLENG1-BaL-eGFP, a derivative of NLENG1-IRES (<xref ref-type="bibr" rid="c75">75</xref>) with the macrophage tropic BaL envelope) in the Nef reading frame, were generated by PEI transfection of 293T cells. Viral infectivity was titred on TZM-bl cells and for infections of Jurkat-R5 cells and primary CD4&#x002B; T cells an equivalent MOI of 0.05 was used. Infected Jurkat-R5 cells were used 3 days post-infection whereas the primary CD4&#x002B; T cells were used 3&#x2013;5 days postinfection. For viral growth assays in pMacs the cells were infected at an MOI of 0.02 and the cells were harvested in 24 hour periods and infectivity was quantified using Renilla-Glo<sup>&#x00AE;</sup> Luciferase assay (Promega) according to the manufacturers protocol. For the cell-cell infectivity assay, NL-LucR.T2A-infected T cells were added to day 7 differentiated pMacs at a ratio of 1:1, with or without pre-treatment of pMacs with AZT (25 &#x03BC;M), T20 (7.5 &#x03BC;g/ml) or ruxolitinib (10 &#x03BC;M). After 6 hours co-culture, the T cells were removed with a single wash in PBS followed by incubation of the cells in macrophage differentiation media supplemented with 25 &#x03BC;M etoposide for 7 days.</p>
</sec>
<sec id="s4e">
<title>Cytokine release</title>
<p>Supernatant from day 7 co-cultures were assayed by Luminex using an 11-plex custom cytokine panel (Affymetrix) according to the manufactures guidelines, except with the addition of a final fixation with 2&#x0025; paraformaldehyde for 30 mins at room temperature and two washes before resuspension in reading buffer. Cytokines included IFN-&#x03B1;, IFN-&#x03B2;, IFN-&#x03B3;, TNF-&#x03B1;, IL-10, IL-1&#x03B2;, IL-6, IL-8, IP-10, MCP-1 and RANTES.</p>
</sec>
<sec id="s4f">
<title>Imaging of Co-cultures</title>
<p>Day seven differentiated pMacs were stained with 2 &#x03BC;M CellTraker<sup>&#x2122;</sup> Orange CMRA before addition of Jurkat-R5 cells, infected 5 days previously with NLENG1-BaL-GFP, at a 2:1 ratio in macrophage differentiation media with 1 &#x03BC;g/ml Hoechst 33342. Cells were imaged on a Zeiss Axiovert 200 microscope with Axiovision MRm camera and Colibri illumination every 5 minutes for 2 hours. Images were processed with Axiovision software (Zeiss) and the fate of all GFP labelled T cells across four fields of view per condition were quantified in a double blind manner.</p>
</sec>
<sec id="s4g">
<title>Western Blot</title>
<p>CEM-H0-BaL or CEM-H0 T cells were added to 7 day differentiated pMacs at a 3:2 ratio for 16 hours in the presence or absence of 250 nM CCR5 antagonist Tak779 or 7.5 &#x03BC;g/ml T20. Cells lysates (20 &#x03BC;g per lane) were prepared with RIPA buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1&#x0025; NP-40, 1&#x0025; sodium deoxycholate, 0.1&#x0025; SDS), containing protease inhibitor cocktail (Sigma) and phosphatase inhibitors (sodium othovanadate, sodium fluoride and beta-glycerophosphate), and were separated on NuPAGE Bis-Tris gels (Thermofisher) and transferred onto PVDF membranes. Membranes were probed with mouse anti-SAMHD1 (2D7, Origene, 1:2000), rabbit anti-phT592-SAMHD1 (Cell Signalling Technology, 1:1000) and rabbit anti-GAPDH (Sigma,1:5000) and quantified using the Odyssey far red imager (LiCor).</p>
</sec>
</sec>
</body>
<back>
<sec>
<p>Supplemental Fig 1</p>
<p>Endogenous expression of TRIMCyp is restrictive to HIV-1 in pluripotent stem cells. Serial dilutions of a VSV-G pseudotyped lentiviral vector were used to infect pluripotent stem cells of the wildtype clone (TRIM5&#x03B1;) and the genetically modified line (TRIMCyp). The multiplicity of infection (MOI) at different dilutions of virus, as measured by flow cytometry for the reporter gene eGFP, are shown as the mean &#x002B;/- standard deviation of a representative experiment performed in triplicate. (A-E) depict different combinations of cell types and treatments (CsA at 5&#x03BC;M) for clarity, all of which is summarized in <xref ref-type="fig" rid="fig1">Fig. 1C.</xref> (F) Schematic representation of the interplay between HIV-1 core (image adapted from (<xref ref-type="bibr" rid="c76">76</xref>), the PRYSPRY domain of TRIM5&#x03B1; (red), the Cyp domain of TRIMCyp (blue) and the host cyclophilin A (blue ovals) in the presence and absence of cyclosporin A (CsA).</p>
<p>Supplemental Fig 2</p>
<p>Endogenous expression of TRIMCyp is restrictive to HIV-1 in stem cell-derived macrophages. Serial dilutions of a VSV-G-pseudotyped eGFP-expressing lentiviral vector were used to infect pMacs derived from the wildtype stem cell clone (TRIM5&#x03B1;) and the genetically modified line (TRIMCyp). The multiplicity of infection (MOI) at different dilutions of virus, as measured by flow cytometry for the reporter gene eGFP, are shown as the mean &#x002B;/-standard deviation of four independent experiments. (A-E) depict different combinations of cell types and treatments (CsA at 5&#x03BC;M) for clarity, all of which is summerised in <xref ref-type="fig" rid="fig1">Fig. 1D.</xref></p>
<p>Supplemental Fig 3</p>
<p>Cell-cell interactions in co-cultures of pMacs and HIV-1 infected T cells. Jurkat-R5 cells, infected with a replication-competent eGFP-reporter virus, were co-cultured with CellTracker Red labeled pMacs and imaged over time. Representative images are shown depicting (A) cell capture (phagocytosis), (B) apoptosis followed by phagocytosis, (C) GFP loss (cell lysis), (D) viral transfer (highlighted with white arrow). (E) Effect of fusion on SAMHD1 phosphorylation. A representative western blot shows the level of total (SAMHD1) and T592-phosphorylated (P-SAMHD1) SAMHD1 as well as the loading control (GAPDH). Macrophages alone (pMac only), CEM T cells alone (CEM only), and co-cultured cells incapable of fusing either through lack of HIV-1 envelope (pMac&#x002B;CEM) or addition of a fusion inhibitor (pMac&#x002B;CEMH0-BaL&#x002B;Tak779) were compared to co-cultures allowed to fuse (pMac&#x002B;CEMH0-BaL).</p>
<p>Supplemental Fig 4</p>
<p>Quality control of the TRIMCyp stem cells and pMacs. (A) SNP analysis (OmniExpress24 chip) of the parental line, wildtype clone (TRIM5&#x03B1;) and modified line (TRIMCyp) are shown, analysed using KaryoStudio (Illumina) to detect copy number variations across the genomes. Duplications are shown in green, deletions in red and loss of heterozygosity in grey. (B) Flow cytometry analysis of antibody staining for key pluripotent stem cell markers, TRA-1&#x2013;60 and NANOG (dark grey), on the stem cell clones of wildtype and genetically modified cell lines versus their respective isotype controls (light grey). Stem cells were fixed in 2&#x0025; paraformaldehyde, followed by re-suspension in ice-cold 100&#x0025; methanol before washing in FACS buffer (PBS with 10 &#x03BC;g/ml IgG from human serum, and 2.5&#x0025; FBS). Antibodies used included anti-Tra-1&#x2013;60-Alexa<sup>488</sup> (Biolegend), anti-NANOG-Alexa<sup>647</sup> (Cell Signaling) and isotope control antibodies IgM-Alexa<sup>488</sup> (Biolegend) and IgG-Alexa<sup>647</sup> (Cell Signaling). (C) Flow cytometry analysis of antibody staining (dark grey) for the myeloid specific lineage marker CD14 and CD68, versus their isotype controls (light grey) on pMacs differentiated from the wildtype and modified cell lines. Antibodies used included anti-CD14-FITC, anti CD68-FITC and their respective isotype controls (all from Immunotools).</p>
<p>Supplemental Video 1</p>
<p>Macrophage infection though cell-cell fusion. HIV-1 eGFP-reporter virus infected Jurkat-R5 cells (green) were cultured with CellTracker Red labelled stem cell-derived macrophages (red), in the presence of Hoechst 33342 to identify nuclei and imaged every 5 minutes. The video shown is a representative video of those used to generated data for <xref ref-type="fig" rid="fig3">Fig 3A&#x002B;B</xref>&#x002B;S3. Multiple fusion events can be observed as eGFP expressed from the T cells is rapidly transferred to the macrophages.</p>
</sec>
<ack>
<title>Acknowledgments</title>
<p>This publication arises from research funded by the John Fell Oxford University Press (OUP) Research Fund. The pluripotent stem cell lines used in this study was originally generated from donor samples supplied by the Oxford Parkinson&#x2019;s Disease Centre (OPDC) study (funded by the Monument Trust Discovery Award from Parkinson&#x2019;s UK, a charity registered in England and Wales (2581970) and in Scotland (SC037554), with the support of the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre based at Oxford University Hospitals NHS Trust and University of Oxford, and the NIHR Comprehensive Local Research Network), and was reprogrammed within StemBANCC, (supported by the Innovative Medicines Initiative Joint Undertaking under grant agreement number 115439, resources of which are composed of financial contribution from the European Union&#x2019;s Seventh Framework Program (FP7/2007e2013) and EFPIA companies&#x2019; in kind contribution). AV-J and LN are supported by the Infection, Immunology and Translation Medicine Wellcome Trust-funded DTC (grant numbers 203805/Z/16/Z and 108869/Z/15/Z, respectively). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</p>
</ack>
<sec id="s5">
<title>Conflict of interest</title>
<p>The authors declare that they have no conflicts of interest with the contents of this article.</p>
</sec>
<sec id="s6">
<title>Author Contributions</title>
<p>MDM designed, carried out, experiments, analysed data and prepared the manuscript. HO, AV-J, LN, JV carried out experiments. WJ and AVJ analysed data and prepared the manuscript.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="journal"><string-name><surname>Gordon</surname> <given-names>S</given-names></string-name>, <string-name><surname>Pluddemann</surname> <given-names>A.</given-names></string-name> <year>2017</year>. <article-title>Tissue macrophages: heterogeneity and functions</article-title>. <source>BMC Biol</source> <volume>15</volume>:<issue>53</issue>.</mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="journal"><string-name><surname>Hoeffel</surname> <given-names>G</given-names></string-name>, <string-name><surname>Ginhoux</surname> <given-names>F.</given-names></string-name> <year>2015</year>. <article-title>Ontogeny of Tissue-Resident Macrophages</article-title>. <source>Front Immunol</source> <volume>6</volume>:<issue>486</issue>.</mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="journal"><string-name><surname>Stremlau</surname> <given-names>M</given-names></string-name>, <string-name><surname>Owens</surname> <given-names>CM</given-names></string-name>, <string-name><surname>Perron</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Kiessling</surname> <given-names>M</given-names></string-name>, <string-name><surname>Autissier</surname> <given-names>P</given-names></string-name>, <string-name><surname>Sodroski</surname> <given-names>J.</given-names></string-name> <year>2004</year>. <article-title>The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys</article-title>. <source>Nature</source> <volume>427</volume>:<issue>848853</issue>.</mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="journal"><string-name><surname>Luban</surname> <given-names>J.</given-names></string-name> <year>2012</year>. <article-title>TRIM5 and the Regulation of HIV-1 Infectivity</article-title>. <source>Mol Biol Int</source> <volume>2012</volume>:<issue>426840</issue>.</mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="journal"><string-name><surname>Stremlau</surname> <given-names>M</given-names></string-name>, <string-name><surname>Perron</surname> <given-names>M</given-names></string-name>, <string-name><surname>Welikala</surname> <given-names>S</given-names></string-name>, <string-name><surname>Sodroski</surname> <given-names>J.</given-names></string-name> <year>2005</year>. <article-title>Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction</article-title>. <source>J Virol</source> <volume>79</volume>:<fpage>3139</fpage>&#x2013;<lpage>3145</lpage>.</mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="journal"><string-name><surname>Wu</surname> <given-names>F</given-names></string-name>, <string-name><surname>Kirmaier</surname> <given-names>A</given-names></string-name>, <string-name><surname>Goeken</surname> <given-names>R</given-names></string-name>, <string-name><surname>Ourmanov</surname> <given-names>I</given-names></string-name>, <string-name><surname>Hall</surname> <given-names>L</given-names></string-name>, <string-name><surname>Morgan</surname> <given-names>JS</given-names></string-name>, <string-name><surname>Matsuda</surname> <given-names>K</given-names></string-name>, <string-name><surname>Buckler-White</surname> <given-names>A</given-names></string-name>, <string-name><surname>Tomioka</surname> <given-names>K</given-names></string-name>, <string-name><surname>Plishka</surname> <given-names>R</given-names></string-name>, <string-name><surname>Whitted</surname> <given-names>S</given-names></string-name>, <string-name><surname>Johnson</surname> <given-names>W</given-names></string-name>, <string-name><surname>Hirsch</surname> <given-names>VM.</given-names></string-name> <year>2013</year>. <article-title>TRIM5 alpha drives SIVsmm evolution in rhesus macaques</article-title>. <source>PLoS Pathog</source> <volume>9</volume>:<fpage>e1003577</fpage>.</mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="journal"><string-name><surname>Yap</surname> <given-names>MW</given-names></string-name>, <string-name><surname>Nisole</surname> <given-names>S</given-names></string-name>, <string-name><surname>Stoye</surname> <given-names>JP.</given-names></string-name> <year>2005</year>. <article-title>A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction</article-title>. <source>Curr Biol</source> <volume>15</volume>:<fpage>73</fpage>&#x2013;<lpage>78</lpage>.</mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="journal"><string-name><surname>Keckesova</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Ylinen</surname> <given-names>LM</given-names></string-name>, <string-name><surname>Towers</surname> <given-names>GJ.</given-names></string-name> <year>2006</year>. <article-title>Cyclophilin A renders human immunodeficiency virus type 1 sensitive to Old World monkey but not human TRIM5 alpha antiviral activity</article-title>. <source>J Virol</source> <volume>80</volume>:<fpage>4683</fpage>&#x2013;<lpage>4690</lpage>.</mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="journal"><string-name><surname>Rasaiyaah</surname> <given-names>J</given-names></string-name>, <string-name><surname>Tan</surname> <given-names>CP</given-names></string-name>, <string-name><surname>Fletcher</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Price</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Blondeau</surname> <given-names>C</given-names></string-name>, <string-name><surname>Hilditch</surname> <given-names>L</given-names></string-name>, <string-name><surname>Jacques</surname> <given-names>DA</given-names></string-name>, <string-name><surname>Selwood</surname> <given-names>DL</given-names></string-name>, <string-name><surname>James</surname> <given-names>LC</given-names></string-name>, <string-name><surname>Noursadeghi</surname> <given-names>M</given-names></string-name>, <string-name><surname>Towers</surname> <given-names>GJ.</given-names></string-name> <year>2013</year>. <article-title>HIV-1 evades innate immune recognition through specific cofactor recruitment</article-title>. <source>Nature</source> <volume>503</volume>:<fpage>402</fpage>&#x2013;<lpage>405</lpage>.</mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="journal"><string-name><surname>Virgen</surname> <given-names>CA</given-names></string-name>, <string-name><surname>Kratovac</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Bieniasz</surname> <given-names>PD</given-names></string-name>, <string-name><surname>Hatziioannou</surname> <given-names>T.</given-names></string-name> <year>2008</year>. <article-title>Independent genesis of chimeric TRIM5-cyclophilin proteins in two primate species</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>105</volume>:<fpage>3563</fpage>&#x2013;<lpage>3568</lpage>.</mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="journal"><string-name><surname>Wilson</surname> <given-names>SJ</given-names></string-name>, <string-name><surname>Webb</surname> <given-names>BL</given-names></string-name>, <string-name><surname>Ylinen</surname> <given-names>LM</given-names></string-name>, <string-name><surname>Verschoor</surname> <given-names>E</given-names></string-name>, <string-name><surname>Heeney</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Towers</surname> <given-names>GJ.</given-names></string-name> <year>2008</year>. <article-title>Independent evolution of an antiviral TRIMCyp in rhesus macaques</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>105</volume>:<fpage>3557</fpage>&#x2013;<lpage>3562</lpage>.</mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="journal"><string-name><surname>Kirmaier</surname> <given-names>A</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>F</given-names></string-name>, <string-name><surname>Newman</surname> <given-names>RM</given-names></string-name>, <string-name><surname>Hall</surname> <given-names>LR</given-names></string-name>, <string-name><surname>Morgan</surname> <given-names>JS</given-names></string-name>, <string-name><surname>O&#x2019;Connor</surname> <given-names>S</given-names></string-name>, <string-name><surname>Marx</surname> <given-names>PA</given-names></string-name>, <string-name><surname>Meythaler</surname> <given-names>M</given-names></string-name>, <string-name><surname>Goldstein</surname> <given-names>S</given-names></string-name>, <string-name><surname>Buckler-White</surname> <given-names>A</given-names></string-name>, <string-name><surname>Kaur</surname> <given-names>A</given-names></string-name>, <string-name><surname>Hirsch</surname> <given-names>VM</given-names></string-name>, <string-name><surname>Johnson</surname> <given-names>WE.</given-names></string-name> <year>2010</year>. <article-title>TRIM5 suppresses cross-species transmission of a primate immunodeficiency virus and selects for emergence of resistant variants in the new species</article-title>. <source>PLoS Biol</source> <volume>8</volume>.</mixed-citation></ref>
<ref id="c13"><label>13.</label><mixed-citation publication-type="journal"><string-name><surname>Nakayama</surname> <given-names>EE</given-names></string-name>, <string-name><surname>Shioda</surname> <given-names>T.</given-names></string-name> <year>2012</year>. <article-title>TRIM5alpha and Species Tropism of HIV/SIV</article-title>. <source>Front Microbiol</source> <volume>3</volume>:<issue>13</issue>.</mixed-citation></ref>
<ref id="c14"><label>14.</label><mixed-citation publication-type="journal"><string-name><surname>Chan</surname> <given-names>E</given-names></string-name>, <string-name><surname>Schaller</surname> <given-names>T</given-names></string-name>, <string-name><surname>Eddaoudi</surname> <given-names>A</given-names></string-name>, <string-name><surname>Zhan</surname> <given-names>H</given-names></string-name>, <string-name><surname>Tan</surname> <given-names>CP</given-names></string-name>, <string-name><surname>Jacobsen</surname> <given-names>M</given-names></string-name>, <string-name><surname>Thrasher</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Towers</surname> <given-names>GJ</given-names></string-name>, <string-name><surname>Qasim</surname> <given-names>W.</given-names></string-name> <year>2012</year>. <article-title>Lentiviral gene therapy against human immunodeficiency virus type 1, using a novel human TRIM21-cyclophilin A restriction factor</article-title>. <source>Hum Gene Ther</source> <volume>23</volume>:<fpage>1176</fpage>&#x2013;<lpage>1185</lpage>.</mixed-citation></ref>
<ref id="c15"><label>15.</label><mixed-citation publication-type="journal"><string-name><surname>Chan</surname> <given-names>E</given-names></string-name>, <string-name><surname>Towers</surname> <given-names>GJ</given-names></string-name>, <string-name><surname>Qasim</surname> <given-names>W.</given-names></string-name> <year>2014</year>. <article-title>Gene therapy strategies to exploit TRIM derived restriction factors against HIV-1</article-title>. <source>Viruses</source> <volume>6</volume>:<fpage>243</fpage>&#x2013;<lpage>263</lpage>.</mixed-citation></ref>
<ref id="c16"><label>16.</label><mixed-citation publication-type="journal"><string-name><surname>Pertel</surname> <given-names>T</given-names></string-name>, <string-name><surname>Hausmann</surname> <given-names>S</given-names></string-name>, <string-name><surname>Morger</surname> <given-names>D</given-names></string-name>, <string-name><surname>Zuger</surname> <given-names>S</given-names></string-name>, <string-name><surname>Guerra</surname> <given-names>J</given-names></string-name>, <string-name><surname>Lascano</surname> <given-names>J</given-names></string-name>, <string-name><surname>Reinhard</surname> <given-names>C</given-names></string-name>, <string-name><surname>Santoni</surname> <given-names>FA</given-names></string-name>, <string-name><surname>Uchil</surname> <given-names>PD</given-names></string-name>, <string-name><surname>Chatel</surname> <given-names>L</given-names></string-name>, <string-name><surname>Bisiaux</surname> <given-names>A</given-names></string-name>, <string-name><surname>Albert</surname> <given-names>ML</given-names></string-name>, <string-name><surname>Strambio-De-Castillia</surname> <given-names>C</given-names></string-name>, <string-name><surname>Mothes</surname> <given-names>W</given-names></string-name>, <string-name><surname>Pizzato</surname> <given-names>M</given-names></string-name>, <string-name><surname>Grutter</surname> <given-names>MG</given-names></string-name>, <string-name><surname>Luban</surname> <given-names>J.</given-names></string-name> <year>2011</year>. <article-title>TRIM5 is an innate immune sensor for the retrovirus capsid lattice</article-title>. <source>Nature</source> <volume>472</volume>:<fpage>361</fpage>&#x2013;<lpage>365</lpage>.</mixed-citation></ref>
<ref id="c17"><label>17.</label><mixed-citation publication-type="journal"><string-name><surname>Goldstone</surname> <given-names>DC</given-names></string-name>, <string-name><surname>Ennis-Adeniran</surname> <given-names>V</given-names></string-name>, <string-name><surname>Hedden</surname> <given-names>JJ</given-names></string-name>, <string-name><surname>Groom</surname> <given-names>HC</given-names></string-name>, <string-name><surname>Rice</surname> <given-names>GI</given-names></string-name>, <string-name><surname>Christodoulou</surname> <given-names>E</given-names></string-name>, <string-name><surname>Walker</surname> <given-names>PA</given-names></string-name>, <string-name><surname>Kelly</surname> <given-names>G</given-names></string-name>, <string-name><surname>Haire</surname> <given-names>LF</given-names></string-name>, <string-name><surname>Yap</surname> <given-names>MW</given-names></string-name>, <string-name><surname>de Carvalho</surname> <given-names>LP</given-names></string-name>, <string-name><surname>Stoye</surname> <given-names>JP</given-names></string-name>, <string-name><surname>Crow</surname> <given-names>YJ</given-names></string-name>, <string-name><surname>Taylor</surname> <given-names>IA</given-names></string-name>, <string-name><surname>Webb</surname> <given-names>M.</given-names></string-name> <year>2011</year>. <article-title>HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase</article-title>. <source>Nature</source> <volume>480</volume>:<fpage>379</fpage>&#x2013;<lpage>382</lpage>.</mixed-citation></ref>
<ref id="c18"><label>18.</label><mixed-citation publication-type="journal"><string-name><surname>Franzolin</surname> <given-names>E</given-names></string-name>, <string-name><surname>Pontarin</surname> <given-names>G</given-names></string-name>, <string-name><surname>Rampazzo</surname> <given-names>C</given-names></string-name>, <string-name><surname>Miazzi</surname> <given-names>C</given-names></string-name>, <string-name><surname>Ferraro</surname> <given-names>P</given-names></string-name>, <string-name><surname>Palumbo</surname> <given-names>E</given-names></string-name>, <string-name><surname>Reichard</surname> <given-names>P</given-names></string-name>, <string-name><surname>Bianchi</surname> <given-names>V.</given-names></string-name> <year>2013</year>. <article-title>The deoxynucleotide triphosphohydrolase SAMHD1 is a major regulator of DNA precursor pools in mammalian cells</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>110</volume>:<fpage>14272</fpage>&#x2013;<lpage>14277</lpage>.</mixed-citation></ref>
<ref id="c19"><label>19.</label><mixed-citation publication-type="journal"><string-name><surname>Lahouassa</surname> <given-names>H</given-names></string-name>, <string-name><surname>Daddacha</surname> <given-names>W</given-names></string-name>, <string-name><surname>Hofmann</surname> <given-names>H</given-names></string-name>, <string-name><surname>Ayinde</surname> <given-names>D</given-names></string-name>, <string-name><surname>Logue</surname> <given-names>EC</given-names></string-name>, <string-name><surname>Dragin</surname> <given-names>L</given-names></string-name>, <string-name><surname>Bloch</surname> <given-names>N</given-names></string-name>, <string-name><surname>Maudet</surname> <given-names>C</given-names></string-name>, <string-name><surname>Bertrand</surname> <given-names>M</given-names></string-name>, <string-name><surname>Gramberg</surname> <given-names>T</given-names></string-name>, <string-name><surname>Pancino</surname> <given-names>G</given-names></string-name>, <string-name><surname>Priet</surname> <given-names>S</given-names></string-name>, <string-name><surname>Canard</surname> <given-names>B</given-names></string-name>, <string-name><surname>Laguette</surname> <given-names>N</given-names></string-name>, <string-name><surname>Benkirane</surname> <given-names>M</given-names></string-name>, <string-name><surname>Transy</surname> <given-names>C</given-names></string-name>, <string-name><surname>Landau</surname> <given-names>NR</given-names></string-name>, <string-name><surname>Kim</surname> <given-names>B</given-names></string-name>, <string-name><surname>Margottin-Goguet</surname> <given-names>F.</given-names></string-name> <year>2012</year>. <article-title>SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates</article-title>. <source>Nat Immunol</source> <volume>13</volume>:<fpage>223</fpage>&#x2013;<lpage>228</lpage>.</mixed-citation></ref>
<ref id="c20"><label>20.</label><mixed-citation publication-type="journal"><string-name><surname>Mock</surname> <given-names>DJ</given-names></string-name>, <string-name><surname>Hollenbaugh</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Daddacha</surname> <given-names>W</given-names></string-name>, <string-name><surname>Overstreet</surname> <given-names>MG</given-names></string-name>, <string-name><surname>Lazarski</surname> <given-names>CA</given-names></string-name>, <string-name><surname>Fowell</surname> <given-names>DJ</given-names></string-name>, <string-name><surname>Kim</surname> <given-names>B.</given-names></string-name> <year>2012</year>. <article-title>Leishmania induces survival, proliferation and elevated cellular dNTP levels in human monocytes promoting acceleration of HIV co-infection</article-title>. <source>PLoS Pathog</source> <volume>8</volume>:<fpage>e1002635</fpage>.</mixed-citation></ref>
<ref id="c21"><label>21.</label><mixed-citation publication-type="journal"><string-name><surname>Schmidt</surname> <given-names>S</given-names></string-name>, <string-name><surname>Schenkova</surname> <given-names>K</given-names></string-name>, <string-name><surname>Adam</surname> <given-names>T</given-names></string-name>, <string-name><surname>Erikson</surname> <given-names>E</given-names></string-name>, <string-name><surname>Lehmann-Koch</surname> <given-names>J</given-names></string-name>, <string-name><surname>Sertel</surname> <given-names>S</given-names></string-name>, <string-name><surname>Verhasselt</surname> <given-names>B</given-names></string-name>, <string-name><surname>Fackler</surname> <given-names>OT</given-names></string-name>, <string-name><surname>Lasitschka</surname> <given-names>F</given-names></string-name>, <string-name><surname>Keppler</surname> <given-names>OT.</given-names></string-name> <year>2015</year>. <article-title>SAMHD1&#x2019;s protein expression profile in humans</article-title>. <source>J Leukoc Biol</source> <volume>98</volume>:<fpage>5</fpage>&#x2013;<lpage>14</lpage>.</mixed-citation></ref>
<ref id="c22"><label>22.</label><mixed-citation publication-type="journal"><string-name><surname>de Silva</surname> <given-names>S</given-names></string-name>, <string-name><surname>Hoy</surname> <given-names>H</given-names></string-name>, <string-name><surname>Hake</surname> <given-names>TS</given-names></string-name>, <string-name><surname>Wong</surname> <given-names>HK</given-names></string-name>, <string-name><surname>Porcu</surname> <given-names>P</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>L.</given-names></string-name> <year>2013</year>. <article-title>Promoter methylation regulates SAMHD1 gene expression in human CD4&#x002B; T cells</article-title>. <source>J Biol Chem</source> <volume>288</volume>:<fpage>9284</fpage>&#x2013;<lpage>9292</lpage>.</mixed-citation></ref>
<ref id="c23"><label>23.</label><mixed-citation publication-type="journal"><string-name><surname>Ruffin</surname> <given-names>N</given-names></string-name>, <string-name><surname>Brezar</surname> <given-names>V</given-names></string-name>, <string-name><surname>Ayinde</surname> <given-names>D</given-names></string-name>, <string-name><surname>Lefebvre</surname> <given-names>C</given-names></string-name>, <string-name><surname>Schulze Zur</surname> <given-names>Wiesch J</given-names></string-name>, <string-name><surname>van Lunzen</surname> <given-names>J</given-names></string-name>, <string-name><surname>Bockhorn</surname> <given-names>M</given-names></string-name>, <string-name><surname>Schwartz</surname> <given-names>O</given-names></string-name>, <string-name><surname>Hocini</surname> <given-names>H</given-names></string-name>, <string-name><surname>Lelievre</surname> <given-names>JD</given-names></string-name>, <string-name><surname>Banchereau</surname> <given-names>J</given-names></string-name>, <string-name><surname>Levy</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Seddiki</surname> <given-names>N.</given-names></string-name> <year>2015</year>. <article-title>Low SAMHD1 expression following T-cell activation and proliferation renders CD4&#x002B; T cells susceptible to HIV-1</article-title>. <source>AIDS</source> <volume>29</volume>:<fpage>519</fpage>&#x2013;<lpage>530</lpage>.</mixed-citation></ref>
<ref id="c24"><label>24.</label><mixed-citation publication-type="journal"><string-name><surname>Laguette</surname> <given-names>N</given-names></string-name>, <string-name><surname>Sobhian</surname> <given-names>B</given-names></string-name>, <string-name><surname>Casartelli</surname> <given-names>N</given-names></string-name>, <string-name><surname>Ringeard</surname> <given-names>M</given-names></string-name>, <string-name><surname>Chable-Bessia</surname> <given-names>C</given-names></string-name>, <string-name><surname>Segeral</surname> <given-names>E</given-names></string-name>, <string-name><surname>Yatim</surname> <given-names>A</given-names></string-name>, <string-name><surname>Emiliani</surname> <given-names>S</given-names></string-name>, <string-name><surname>Schwartz</surname> <given-names>O</given-names></string-name>, <string-name><surname>Benkirane</surname> <given-names>M.</given-names></string-name> <year>2011</year>. <article-title>SAMHD1 is the dendritic-and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx</article-title>. <source>Nature</source> <volume>474</volume>:<fpage>654</fpage>&#x2013;<lpage>657</lpage>.</mixed-citation></ref>
<ref id="c25"><label>25.</label><mixed-citation publication-type="journal"><string-name><surname>Buchrieser</surname> <given-names>J</given-names></string-name>, <string-name><surname>James</surname> <given-names>W</given-names></string-name>, <string-name><surname>Moore</surname> <given-names>MD.</given-names></string-name> <year>2017</year>. <article-title>Human Induced Pluripotent Stem Cell-Derived Macrophages Share Ontogeny with MYB-Independent Tissue-Resident Macrophages</article-title>. <source>Stem Cell Reports</source> <volume>8</volume>:<fpage>334</fpage>&#x2013;<lpage>345</lpage>.</mixed-citation></ref>
<ref id="c26"><label>26.</label><mixed-citation publication-type="journal"><string-name><surname>Haenseler</surname> <given-names>W</given-names></string-name>, <string-name><surname>Sansom</surname> <given-names>SN</given-names></string-name>, <string-name><surname>Buchrieser</surname> <given-names>J</given-names></string-name>, <string-name><surname>Newey</surname> <given-names>SE</given-names></string-name>, <string-name><surname>Moore</surname> <given-names>CS</given-names></string-name>, <string-name><surname>Nicholls</surname> <given-names>FJ</given-names></string-name>, <string-name><surname>Chintawar</surname> <given-names>S</given-names></string-name>, <string-name><surname>Schnell</surname> <given-names>C</given-names></string-name>, <string-name><surname>Antel</surname> <given-names>JP</given-names></string-name>, <string-name><surname>Allen</surname> <given-names>ND</given-names></string-name>, <string-name><surname>Cader</surname> <given-names>MZ</given-names></string-name>, <string-name><surname>Wade-Martins</surname> <given-names>R</given-names></string-name>, <string-name><surname>James</surname> <given-names>WS</given-names></string-name>, <string-name><surname>Cowley</surname> <given-names>SA.</given-names></string-name> <year>2017</year>. <article-title>A Highly Efficient Human Pluripotent Stem Cell Microglia Model Displays a Neuronal-Co-culture-Specific Expression Profile and Inflammatory Response</article-title>. <source>Stem Cell Reports</source> <volume>8</volume>:<fpage>1727</fpage>&#x2013;<lpage>1742</lpage>.</mixed-citation></ref>
<ref id="c27"><label>27.</label><mixed-citation publication-type="journal"><string-name><surname>Ran</surname> <given-names>FA</given-names></string-name>, <string-name><surname>Hsu</surname> <given-names>PD</given-names></string-name>, <string-name><surname>Lin</surname> <given-names>CY</given-names></string-name>, <string-name><surname>Gootenberg</surname> <given-names>JS</given-names></string-name>, <string-name><surname>Konermann</surname> <given-names>S</given-names></string-name>, <string-name><surname>Trevino</surname> <given-names>AE</given-names></string-name>, <string-name><surname>Scott</surname> <given-names>DA</given-names></string-name>, <string-name><surname>Inoue</surname> <given-names>A</given-names></string-name>, <string-name><surname>Matoba</surname> <given-names>S</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>F.</given-names></string-name> <year>2013</year>. <article-title>Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity</article-title>. <source>Cell</source> <volume>154</volume>:<fpage>1380</fpage>&#x2013;<lpage>1389</lpage>.</mixed-citation></ref>
<ref id="c28"><label>28.</label><mixed-citation publication-type="journal"><string-name><surname>Neagu</surname> <given-names>MR</given-names></string-name>, <string-name><surname>Ziegler</surname> <given-names>P</given-names></string-name>, <string-name><surname>Pertel</surname> <given-names>T</given-names></string-name>, <string-name><surname>Strambio-De-Castillia</surname> <given-names>C</given-names></string-name>, <string-name><surname>Grutter</surname> <given-names>C</given-names></string-name>, <string-name><surname>Martinetti</surname> <given-names>G</given-names></string-name>, <string-name><surname>Mazzucchelli</surname> <given-names>L</given-names></string-name>, <string-name><surname>Grutter</surname> <given-names>M</given-names></string-name>, <string-name><surname>Manz</surname> <given-names>MG</given-names></string-name>, <string-name><surname>Luban</surname> <given-names>J.</given-names></string-name> <year>2009</year>. <article-title>Potent inhibition of HIV-1 by TRIM5-cyclophilin fusion proteins engineered from human components</article-title>. <source>J Clin Invest</source> <volume>119</volume>:<fpage>3035</fpage>&#x2013;<lpage>3047</lpage>.</mixed-citation></ref>
<ref id="c29"><label>29.</label><mixed-citation publication-type="journal"><string-name><surname>van Wilgenburg</surname> <given-names>B</given-names></string-name>, <string-name><surname>Browne</surname> <given-names>C</given-names></string-name>, <string-name><surname>Vowles</surname> <given-names>J</given-names></string-name>, <string-name><surname>Cowley</surname> <given-names>SA.</given-names></string-name> <year>2013</year>. <article-title>Efficient, long term production of monocyte-derived macrophages from human pluripotent stem cells under partly-defined and fully-defined conditions</article-title>. <source>PLoS One</source> <volume>8</volume>:<fpage>e71098</fpage>.</mixed-citation></ref>
<ref id="c30"><label>30.</label><mixed-citation publication-type="journal"><string-name><surname>Rowe</surname> <given-names>HM</given-names></string-name>, <string-name><surname>Kapopoulou</surname> <given-names>A</given-names></string-name>, <string-name><surname>Corsinotti</surname> <given-names>A</given-names></string-name>, <string-name><surname>Fasching</surname> <given-names>L</given-names></string-name>, <string-name><surname>Macfarlan</surname> <given-names>TS</given-names></string-name>, <string-name><surname>Tarabay</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Viville</surname> <given-names>S</given-names></string-name>, <string-name><surname>Jakobsson</surname> <given-names>J</given-names></string-name>, <string-name><surname>Pfaff</surname> <given-names>SL</given-names></string-name>, <string-name><surname>Trono</surname> <given-names>D.</given-names></string-name> <year>2013</year>. <article-title>TRIM28 repression of retrotransposon-based enhancers is necessary to preserve transcriptional dynamics in embryonic stem cells</article-title>. <source>Genome Res</source> <volume>23</volume>:<issue>452461</issue>.</mixed-citation></ref>
<ref id="c31"><label>31.</label><mixed-citation publication-type="journal"><string-name><surname>Shi</surname> <given-names>J</given-names></string-name>, <string-name><surname>Aiken</surname> <given-names>C.</given-names></string-name> <year>2006</year>. <article-title>Saturation of TRIM5 alpha-mediated restriction of HIV-1 infection depends on the stability of the incoming viral capsid</article-title>. <source>Virology</source> <volume>350</volume>:<fpage>493</fpage>&#x2013;<lpage>500</lpage>.</mixed-citation></ref>
<ref id="c32"><label>32.</label><mixed-citation publication-type="journal"><string-name><surname>Hatziioannou</surname> <given-names>T</given-names></string-name>, <string-name><surname>Perez-Caballero</surname> <given-names>D</given-names></string-name>, <string-name><surname>Yang</surname> <given-names>A</given-names></string-name>, <string-name><surname>Cowan</surname> <given-names>S</given-names></string-name>, <string-name><surname>Bieniasz</surname> <given-names>PD.</given-names></string-name> <year>2004</year>. <article-title>Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>101</volume>:<fpage>10774</fpage>&#x2013;<lpage>10779</lpage>.</mixed-citation></ref>
<ref id="c33"><label>33.</label><mixed-citation publication-type="journal"><string-name><surname>Ribeiro</surname> <given-names>CM</given-names></string-name>, <string-name><surname>Sarrami-Forooshani</surname> <given-names>R</given-names></string-name>, <string-name><surname>Setiawan</surname> <given-names>LC</given-names></string-name>, <string-name><surname>Zijlstra-Willems</surname> <given-names>EM</given-names></string-name>, <string-name><surname>van Hamme</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Tigchelaar</surname> <given-names>W</given-names></string-name>, <string-name><surname>van der Wel</surname> <given-names>NN</given-names></string-name>, <string-name><surname>Kootstra</surname> <given-names>NA</given-names></string-name>, <string-name><surname>Gringhuis</surname> <given-names>SI</given-names></string-name>, <string-name><surname>Geijtenbeek</surname> <given-names>TB.</given-names></string-name> <year>2016</year>. <article-title>Receptor usage dictates HIV-1 restriction by human TRIM5alpha in dendritic cell subsets</article-title>. <source>Nature</source> <volume>540</volume>:<issue>448452</issue>.</mixed-citation></ref>
<ref id="c34"><label>34.</label><mixed-citation publication-type="journal"><string-name><surname>D&#x2019;Angelo</surname> <given-names>W</given-names></string-name>, <string-name><surname>Gurung</surname> <given-names>C</given-names></string-name>, <string-name><surname>Acharya</surname> <given-names>D</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>B</given-names></string-name>, <string-name><surname>Ortolano</surname> <given-names>N</given-names></string-name>, <string-name><surname>Gama</surname> <given-names>V</given-names></string-name>, <string-name><surname>Bai</surname> <given-names>F</given-names></string-name>, <string-name><surname>Guo</surname> <given-names>YL.</given-names></string-name> <year>2017</year>. <article-title>The Molecular Basis for the Lack of Inflammatory Responses in Mouse Embryonic Stem Cells and Their Differentiated Cells</article-title>. <source>J Immunol</source> <volume>198</volume>:<fpage>2147</fpage>&#x2013;<lpage>2155</lpage>.</mixed-citation></ref>
<ref id="c35"><label>35.</label><mixed-citation publication-type="journal"><string-name><surname>Pushkarsky</surname> <given-names>T</given-names></string-name>, <string-name><surname>Zybarth</surname> <given-names>G</given-names></string-name>, <string-name><surname>Dubrovsky</surname> <given-names>L</given-names></string-name>, <string-name><surname>Yurchenko</surname> <given-names>V</given-names></string-name>, <string-name><surname>Tang</surname> <given-names>H</given-names></string-name>, <string-name><surname>Guo</surname> <given-names>H</given-names></string-name>, <string-name><surname>Toole</surname> <given-names>B</given-names></string-name>, <string-name><surname>Sherry</surname> <given-names>B</given-names></string-name>, <string-name><surname>Bukrinsky</surname> <given-names>M.</given-names></string-name> <year>2001</year>. <article-title>CD147 facilitates HIV-1 infection by interacting with virus-associated cyclophilin A</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>98</volume>:<fpage>6360</fpage>&#x2013;<lpage>6365</lpage>.</mixed-citation></ref>
<ref id="c36"><label>36.</label><mixed-citation publication-type="journal"><string-name><surname>Duncan</surname> <given-names>CJ</given-names></string-name>, <string-name><surname>Russell</surname> <given-names>RA</given-names></string-name>, <string-name><surname>Sattentau</surname> <given-names>QJ.</given-names></string-name> <year>2013</year>. <article-title>High multiplicity HIV-1 cell-to-cell transmission from macrophages to CD4&#x002B; T cells limits antiretroviral efficacy</article-title>. <source>Aids</source> <volume>27</volume>:<fpage>2201</fpage>&#x2013;<lpage>2206</lpage>.</mixed-citation></ref>
<ref id="c37"><label>37.</label><mixed-citation publication-type="journal"><string-name><surname>Russell</surname> <given-names>RA</given-names></string-name>, <string-name><surname>Martin</surname> <given-names>N</given-names></string-name>, <string-name><surname>Mitar</surname> <given-names>I</given-names></string-name>, <string-name><surname>Jones</surname> <given-names>E</given-names></string-name>, <string-name><surname>Sattentau</surname> <given-names>QJ.</given-names></string-name> <year>2013</year>. <article-title>Multiple proviral integration events after virological synapse-mediated HIV-1 spread</article-title>. <source>Virology</source> <volume>443</volume>:<fpage>143</fpage>&#x2013;<lpage>149</lpage>.</mixed-citation></ref>
<ref id="c38"><label>38.</label><mixed-citation publication-type="journal"><string-name><surname>Baxter</surname> <given-names>AE</given-names></string-name>, <string-name><surname>Russell</surname> <given-names>RA</given-names></string-name>, <string-name><surname>Duncan</surname> <given-names>CJ</given-names></string-name>, <string-name><surname>Moore</surname> <given-names>MD</given-names></string-name>, <string-name><surname>Willberg</surname> <given-names>CB</given-names></string-name>, <string-name><surname>Pablos</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Finzi</surname> <given-names>A</given-names></string-name>, <string-name><surname>Kaufmann</surname> <given-names>DE</given-names></string-name>, <string-name><surname>Ochsenbauer</surname> <given-names>C</given-names></string-name>, <string-name><surname>Kappes</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Groot</surname> <given-names>F</given-names></string-name>, <string-name><surname>Sattentau</surname> <given-names>QJ.</given-names></string-name> <year>2014</year>. <article-title>Macrophage infection via selective capture of HIV-1-infected CD4&#x002B; T cells</article-title>. <source>Cell Host Microbe</source> <volume>16</volume>:<fpage>711</fpage>&#x2013;<lpage>721</lpage>.</mixed-citation></ref>
<ref id="c39"><label>39.</label><mixed-citation publication-type="journal"><string-name><surname>Lalezari</surname> <given-names>JP</given-names></string-name>, <string-name><surname>Eron</surname> <given-names>JJ</given-names></string-name>, <string-name><surname>Carlson</surname> <given-names>M</given-names></string-name>, <string-name><surname>Cohen</surname> <given-names>C</given-names></string-name>, <string-name><surname>DeJesus</surname> <given-names>E</given-names></string-name>, <string-name><surname>Arduino</surname> <given-names>RC</given-names></string-name>, <string-name><surname>Gallant</surname> <given-names>JE</given-names></string-name>, <string-name><surname>Volberding</surname> <given-names>P</given-names></string-name>, <string-name><surname>Murphy</surname> <given-names>RL</given-names></string-name>, <string-name><surname>Valentine</surname> <given-names>F</given-names></string-name>, <string-name><surname>Nelson</surname> <given-names>EL</given-names></string-name>, <string-name><surname>Sista</surname> <given-names>PR</given-names></string-name>, <string-name><surname>Dusek</surname> <given-names>A</given-names></string-name>, <string-name><surname>Kilby</surname> <given-names>JM.</given-names></string-name> <year>2003</year>. <article-title>A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy</article-title>. <source>AIDS</source> <volume>17</volume>:<fpage>691</fpage>&#x2013;<lpage>698</lpage>.</mixed-citation></ref>
<ref id="c40"><label>40.</label><mixed-citation publication-type="journal"><string-name><surname>Dargent</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Lespagnard</surname> <given-names>L</given-names></string-name>, <string-name><surname>Kornreich</surname> <given-names>A</given-names></string-name>, <string-name><surname>Hermans</surname> <given-names>P</given-names></string-name>, <string-name><surname>Clumeck</surname> <given-names>N</given-names></string-name>, <string-name><surname>Verhest</surname> <given-names>A.</given-names></string-name> <year>2000</year>. <article-title>HIV-associated multinucleated giant cells in lymphoid tissue of the Waldeyer&#x2019;s ring: a detailed study</article-title>. <source>Mod Pathol</source> <volume>13</volume>:<fpage>1293</fpage>&#x2013;<lpage>1299</lpage>.</mixed-citation></ref>
<ref id="c41"><label>41.</label><mixed-citation publication-type="journal"><string-name><surname>Harbison</surname> <given-names>C</given-names></string-name>, <string-name><surname>Zhuang</surname> <given-names>K</given-names></string-name>, <string-name><surname>Gettie</surname> <given-names>A</given-names></string-name>, <string-name><surname>Blanchard</surname> <given-names>J</given-names></string-name>, <string-name><surname>Knight</surname> <given-names>H</given-names></string-name>, <string-name><surname>Didier</surname> <given-names>P</given-names></string-name>, <string-name><surname>Cheng-Mayer</surname> <given-names>C</given-names></string-name>, <string-name><surname>Westmoreland</surname> <given-names>S.</given-names></string-name> <year>2014</year>. <article-title>Giant cell encephalitis and microglial infection with mucosally transmitted simian-human immunodeficiency virus SHIVSF162P3N in rhesus macaques</article-title>. <source>J Neurovirol</source> <volume>20</volume>:<fpage>62</fpage>&#x2013;<lpage>72</lpage>.</mixed-citation></ref>
<ref id="c42"><label>42.</label><mixed-citation publication-type="journal"><string-name><surname>Gary</surname> <given-names>R</given-names></string-name>, <string-name><surname>Voelkl</surname> <given-names>S</given-names></string-name>, <string-name><surname>Palmisano</surname> <given-names>R</given-names></string-name>, <string-name><surname>Ullrich</surname> <given-names>E</given-names></string-name>, <string-name><surname>Bosch</surname> <given-names>JJ</given-names></string-name>, <string-name><surname>Mackensen</surname> <given-names>A.</given-names></string-name> <year>2012</year>. <article-title>Antigen-specific transfer of functional programmed death ligand 1 from human APCs onto CD8&#x002B; T cells via trogocytosis</article-title>. <source>J Immunol</source> <volume>188</volume>:<fpage>744</fpage>&#x2013;<lpage>752</lpage>.</mixed-citation></ref>
<ref id="c43"><label>43.</label><mixed-citation publication-type="journal"><string-name><surname>Jolly</surname> <given-names>C</given-names></string-name>, <string-name><surname>Kashefi</surname> <given-names>K</given-names></string-name>, <string-name><surname>Hollinshead</surname> <given-names>M</given-names></string-name>, <string-name><surname>Sattentau</surname> <given-names>QJ.</given-names></string-name> <year>2004</year>. <article-title>HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse</article-title>. <source>J Exp Med</source> <volume>199</volume>:<fpage>283</fpage>&#x2013;<lpage>293</lpage>.</mixed-citation></ref>
<ref id="c44"><label>44.</label><mixed-citation publication-type="journal"><string-name><surname>Wills</surname> <given-names>QF</given-names></string-name>, <string-name><surname>Mellado-Gomez</surname> <given-names>E</given-names></string-name>, <string-name><surname>Nolan</surname> <given-names>R</given-names></string-name>, <string-name><surname>Warner</surname> <given-names>D</given-names></string-name>, <string-name><surname>Sharma</surname> <given-names>E</given-names></string-name>, <string-name><surname>Broxholme</surname> <given-names>J</given-names></string-name>, <string-name><surname>Wright</surname> <given-names>B</given-names></string-name>, <string-name><surname>Lockstone</surname> <given-names>H</given-names></string-name>, <string-name><surname>James</surname> <given-names>W</given-names></string-name>, <string-name><surname>Lynch</surname> <given-names>M</given-names></string-name>, <string-name><surname>Gonzales</surname> <given-names>M</given-names></string-name>, <string-name><surname>West</surname> <given-names>J</given-names></string-name>, <string-name><surname>Leyrat</surname> <given-names>A</given-names></string-name>, <string-name><surname>Padilla-Parra</surname> <given-names>S</given-names></string-name>, <string-name><surname>Filippi</surname> <given-names>S</given-names></string-name>, <string-name><surname>Holmes</surname> <given-names>C</given-names></string-name>, <string-name><surname>Moore</surname> <given-names>MD</given-names></string-name>, <string-name><surname>Bowden</surname> <given-names>R.</given-names></string-name> <year>2017</year>. <article-title>The nature and nurture of cell heterogeneity: accounting for macrophage gene-environment interactions with single-cell RNA-Seq</article-title>. <source>BMC Genomics</source> <volume>18</volume>:<issue>53</issue>.</mixed-citation></ref>
<ref id="c45"><label>45.</label><mixed-citation publication-type="journal"><string-name><surname>Avalos</surname> <given-names>CR</given-names></string-name>, <string-name><surname>Abreu</surname> <given-names>CM</given-names></string-name>, <string-name><surname>Queen</surname> <given-names>SE</given-names></string-name>, <string-name><surname>Li</surname> <given-names>M</given-names></string-name>, <string-name><surname>Price</surname> <given-names>S</given-names></string-name>, <string-name><surname>Shirk</surname> <given-names>EN</given-names></string-name>, <string-name><surname>Engle</surname> <given-names>EL</given-names></string-name>, <string-name><surname>Forsyth</surname> <given-names>E</given-names></string-name>, <string-name><surname>Bullock</surname> <given-names>BT</given-names></string-name>, <string-name><surname>Mac Gabhann</surname> <given-names>F</given-names></string-name>, <string-name><surname>Wietgrefe</surname> <given-names>SW</given-names></string-name>, <string-name><surname>Haase</surname> <given-names>AT</given-names></string-name>, <string-name><surname>Zink</surname> <given-names>MC</given-names></string-name>, <string-name><surname>Mankowski</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Clements</surname> <given-names>JE</given-names></string-name>, <string-name><surname>Gama</surname> <given-names>L.</given-names></string-name> <year>2017</year>. <article-title>Brain Macrophages in Simian Immunodeficiency Virus-Infected, Antiretroviral-Suppressed Macaques: a Functional Latent Reservoir</article-title>. <source>MBio</source> <volume>8</volume>.</mixed-citation></ref>
<ref id="c46"><label>46.</label><mixed-citation publication-type="journal"><string-name><surname>Deeks</surname> <given-names>SG</given-names></string-name>, <string-name><surname>Barre-Sinoussi</surname> <given-names>F.</given-names></string-name> <year>2012</year>. <article-title>Public health: Towards a cure for HIV</article-title>. <source>Nature</source> <volume>487</volume>:<fpage>293</fpage>&#x2013;<lpage>294</lpage>.</mixed-citation></ref>
<ref id="c47"><label>47.</label><mixed-citation publication-type="journal"><string-name><surname>Mlcochova</surname> <given-names>P</given-names></string-name>, <string-name><surname>Sutherland</surname> <given-names>KA</given-names></string-name>, <string-name><surname>Watters</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Bertoli</surname> <given-names>C</given-names></string-name>, <string-name><surname>de Bruin</surname> <given-names>RA</given-names></string-name>, <string-name><surname>Rehwinkel</surname> <given-names>J</given-names></string-name>, <string-name><surname>Neil</surname> <given-names>SJ</given-names></string-name>, <string-name><surname>Lenzi</surname> <given-names>GM</given-names></string-name>, <string-name><surname>Kim</surname> <given-names>B</given-names></string-name>, <string-name><surname>Khwaja</surname> <given-names>A</given-names></string-name>, <string-name><surname>Gage</surname> <given-names>MC</given-names></string-name>, <string-name><surname>Georgiou</surname> <given-names>C</given-names></string-name>, <string-name><surname>Chittka</surname> <given-names>A</given-names></string-name>, <string-name><surname>Yona</surname> <given-names>S</given-names></string-name>, <string-name><surname>Noursadeghi</surname> <given-names>M</given-names></string-name>, <string-name><surname>Towers</surname> <given-names>GJ</given-names></string-name>, <string-name><surname>Gupta</surname> <given-names>RK.</given-names></string-name> <year>2017</year>. <article-title>A G1-like state allows HIV-1 to bypass SAMHD1 restriction in macrophages</article-title>. <source>Embo j</source> <volume>36</volume>:<fpage>604</fpage>&#x2013;<lpage>616</lpage>.</mixed-citation></ref>
<ref id="c48"><label>48.</label><mixed-citation publication-type="journal"><string-name><surname>Towers</surname> <given-names>GJ</given-names></string-name>, <string-name><surname>Hatziioannou</surname> <given-names>T</given-names></string-name>, <string-name><surname>Cowan</surname> <given-names>S</given-names></string-name>, <string-name><surname>Goff</surname> <given-names>SP</given-names></string-name>, <string-name><surname>Luban</surname> <given-names>J</given-names></string-name>, <string-name><surname>Bieniasz</surname> <given-names>PD.</given-names></string-name> <year>2003</year>. <article-title>Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors</article-title>. <source>Nat Med</source> <volume>9</volume>:<fpage>1138</fpage>&#x2013;<lpage>1143</lpage>.</mixed-citation></ref>
<ref id="c49"><label>49.</label><mixed-citation publication-type="journal"><string-name><surname>Kellam</surname> <given-names>P</given-names></string-name>, <string-name><surname>Larder</surname> <given-names>BA.</given-names></string-name> <year>1995</year>. <article-title>Retroviral recombination can lead to linkage of reverse transcriptase mutations that confer increased zidovudine resistance</article-title>. <source>J Virol</source> <volume>69</volume>:<fpage>669</fpage>&#x2013;<lpage>674</lpage>.</mixed-citation></ref>
<ref id="c50"><label>50.</label><mixed-citation publication-type="journal"><string-name><surname>Luban</surname> <given-names>J.</given-names></string-name> <year>2007</year>. <article-title>Cyclophilin A, TRIM5, and resistance to human immunodeficiency virus type 1 infection</article-title>. <source>J Virol</source> <volume>81</volume>:<fpage>1054</fpage>&#x2013;<lpage>1061</lpage>.</mixed-citation></ref>
<ref id="c51"><label>51.</label><mixed-citation publication-type="journal"><string-name><surname>Sokolskaja</surname> <given-names>E</given-names></string-name>, <string-name><surname>Berthoux</surname> <given-names>L</given-names></string-name>, <string-name><surname>Luban</surname> <given-names>J.</given-names></string-name> <year>2006</year>. <article-title>Cyclophilin A and TRIM5alpha independently regulate human immunodeficiency virus type 1 infectivity in human cells</article-title>. <source>J Virol</source> <volume>80</volume>:<fpage>2855</fpage>&#x2013;<lpage>2862</lpage>.</mixed-citation></ref>
<ref id="c52"><label>52.</label><mixed-citation publication-type="journal"><string-name><surname>Schaller</surname> <given-names>T</given-names></string-name>, <string-name><surname>Ocwieja</surname> <given-names>KE</given-names></string-name>, <string-name><surname>Rasaiyaah</surname> <given-names>J</given-names></string-name>, <string-name><surname>Price</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Brady</surname> <given-names>TL</given-names></string-name>, <string-name><surname>Roth</surname> <given-names>SL</given-names></string-name>, <string-name><surname>Hue</surname> <given-names>S</given-names></string-name>, <string-name><surname>Fletcher</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>K</given-names></string-name>, <string-name><surname>KewalRamani</surname> <given-names>VN</given-names></string-name>, <string-name><surname>Noursadeghi</surname> <given-names>M</given-names></string-name>, <string-name><surname>Jenner</surname> <given-names>RG</given-names></string-name>, <string-name><surname>James</surname> <given-names>LC</given-names></string-name>, <string-name><surname>Bushman</surname> <given-names>FD</given-names></string-name>, <string-name><surname>Towers</surname> <given-names>GJ.</given-names></string-name> <year>2011</year>. <article-title>HIV-1 capsid-cyclophilin interactions determine nuclear import pathway, integration targeting and replication efficiency</article-title>. <source>PLoS Pathog</source> <volume>7</volume>:<fpage>e1002439</fpage>.</mixed-citation></ref>
<ref id="c53"><label>53.</label><mixed-citation publication-type="journal"><string-name><surname>Campbell</surname> <given-names>EM</given-names></string-name>, <string-name><surname>Weingart</surname> <given-names>J</given-names></string-name>, <string-name><surname>Sette</surname> <given-names>P</given-names></string-name>, <string-name><surname>Opp</surname> <given-names>S</given-names></string-name>, <string-name><surname>Sastri</surname> <given-names>J</given-names></string-name>, <string-name><surname>O&#x2019;Connor</surname> <given-names>SK</given-names></string-name>, <string-name><surname>Talley</surname> <given-names>S</given-names></string-name>, <string-name><surname>Diaz-Griffero</surname> <given-names>F</given-names></string-name>, <string-name><surname>Hirsch</surname> <given-names>V</given-names></string-name>, <string-name><surname>Bouamr</surname> <given-names>F.</given-names></string-name> <year>2016</year>. <article-title>TRIM5alpha-Mediated Ubiquitin Chain Conjugation Is Required for Inhibition of HIV-1 Reverse Transcription and Capsid Destabilization</article-title>. <source>J Virol</source> <volume>90</volume>:<fpage>1849</fpage>&#x2013;<lpage>1857</lpage>.</mixed-citation></ref>
<ref id="c54"><label>54.</label><mixed-citation publication-type="journal"><string-name><surname>Billich</surname> <given-names>A</given-names></string-name>, <string-name><surname>Hammerschmid</surname> <given-names>F</given-names></string-name>, <string-name><surname>Peichl</surname> <given-names>P</given-names></string-name>, <string-name><surname>Wenger</surname> <given-names>R</given-names></string-name>, <string-name><surname>Zenke</surname> <given-names>G</given-names></string-name>, <string-name><surname>Quesniaux</surname> <given-names>V</given-names></string-name>, <string-name><surname>Rosenwirth</surname> <given-names>B.</given-names></string-name> <year>1995</year>. <article-title>Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus (HIV) type 1: interference with HIV protein-cyclophilin A interactions</article-title>. <source>J Virol</source> <volume>69</volume>:<fpage>2451</fpage>&#x2013;<lpage>2461</lpage>.</mixed-citation></ref>
<ref id="c55"><label>55.</label><mixed-citation publication-type="journal"><string-name><surname>Ptak</surname> <given-names>RG</given-names></string-name>, <string-name><surname>Gallay</surname> <given-names>PA</given-names></string-name>, <string-name><surname>Jochmans</surname> <given-names>D</given-names></string-name>, <string-name><surname>Halestrap</surname> <given-names>AP</given-names></string-name>, <string-name><surname>Ruegg</surname> <given-names>UT</given-names></string-name>, <string-name><surname>Pallansch</surname> <given-names>LA</given-names></string-name>, <string-name><surname>Bobardt</surname> <given-names>MD</given-names></string-name>, <string-name><surname>de Bethune</surname> <given-names>MP</given-names></string-name>, <string-name><surname>Neyts</surname> <given-names>J</given-names></string-name>, <string-name><surname>De Clercq</surname> <given-names>E</given-names></string-name>, <string-name><surname>Dumont</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Scalfaro</surname> <given-names>P</given-names></string-name>, <string-name><surname>Besseghir</surname> <given-names>K</given-names></string-name>, <string-name><surname>Wenger</surname> <given-names>RM</given-names></string-name>, <string-name><surname>Rosenwirth</surname> <given-names>B.</given-names></string-name> <year>2008</year>. <article-title>Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent</article-title>. <source>Antimicrob Agents Chemother</source> <volume>52</volume>:<issue>13021317</issue>.</mixed-citation></ref>
<ref id="c56"><label>56.</label><mixed-citation publication-type="journal"><string-name><surname>Flisiak</surname> <given-names>R</given-names></string-name>, <string-name><surname>Horban</surname> <given-names>A</given-names></string-name>, <string-name><surname>Gallay</surname> <given-names>P</given-names></string-name>, <string-name><surname>Bobardt</surname> <given-names>M</given-names></string-name>, <string-name><surname>Selvarajah</surname> <given-names>S</given-names></string-name>, <string-name><surname>Wiercinska-Drapalo</surname> <given-names>A</given-names></string-name>, <string-name><surname>Siwak</surname> <given-names>E</given-names></string-name>, <string-name><surname>Cielniak</surname> <given-names>I</given-names></string-name>, <string-name><surname>Higersberger</surname> <given-names>J</given-names></string-name>, <string-name><surname>Kierkus</surname> <given-names>J</given-names></string-name>, <string-name><surname>Aeschlimann</surname> <given-names>C</given-names></string-name>, <string-name><surname>Grosgurin</surname> <given-names>P</given-names></string-name>, <string-name><surname>Nicolas-Metral</surname> <given-names>V</given-names></string-name>, <string-name><surname>Dumont</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Porchet</surname> <given-names>H</given-names></string-name>, <string-name><surname>Crabbe</surname> <given-names>R</given-names></string-name>, <string-name><surname>Scalfaro</surname> <given-names>P.</given-names></string-name> <year>2008</year>. <article-title>The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus</article-title>. <source>Hepatology</source> <volume>47</volume>:<fpage>817</fpage>&#x2013;<lpage>826</lpage>.</mixed-citation></ref>
<ref id="c57"><label>57.</label><mixed-citation publication-type="journal"><string-name><surname>Rizzardi</surname> <given-names>GP</given-names></string-name>, <string-name><surname>Harari</surname> <given-names>A</given-names></string-name>, <string-name><surname>Capiluppi</surname> <given-names>B</given-names></string-name>, <string-name><surname>Tambussi</surname> <given-names>G</given-names></string-name>, <string-name><surname>Ellefsen</surname> <given-names>K</given-names></string-name>, <string-name><surname>Ciuffreda</surname> <given-names>D</given-names></string-name>, <string-name><surname>Champagne</surname> <given-names>P</given-names></string-name>, <string-name><surname>Bart</surname> <given-names>PA</given-names></string-name>, <string-name><surname>Chave</surname> <given-names>JP</given-names></string-name>, <string-name><surname>Lazzarin</surname> <given-names>A</given-names></string-name>, <string-name><surname>Pantaleo</surname> <given-names>G.</given-names></string-name> <year>2002</year>. <article-title>Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy</article-title>. <source>J Clin Invest</source> <volume>109</volume>:<fpage>681</fpage>&#x2013;<lpage>688</lpage>.</mixed-citation></ref>
<ref id="c58"><label>58.</label><mixed-citation publication-type="journal"><string-name><surname>Markowitz</surname> <given-names>M</given-names></string-name>, <string-name><surname>Vaida</surname> <given-names>F</given-names></string-name>, <string-name><surname>Hare</surname> <given-names>CB</given-names></string-name>, <string-name><surname>Boden</surname> <given-names>D</given-names></string-name>, <string-name><surname>Mohri</surname> <given-names>H</given-names></string-name>, <string-name><surname>Hecht</surname> <given-names>FM</given-names></string-name>, <string-name><surname>Kalayjian</surname> <given-names>RC</given-names></string-name>, <string-name><surname>Conrad</surname> <given-names>A</given-names></string-name>, <string-name><surname>Mildvan</surname> <given-names>D</given-names></string-name>, <string-name><surname>Aberg</surname> <given-names>J</given-names></string-name>, <string-name><surname>Hogan</surname> <given-names>C</given-names></string-name>, <string-name><surname>Kilby</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Balfour</surname> <given-names>HH</given-names>, <suffix>Jr.</suffix></string-name>, <string-name><surname>Schafer</surname> <given-names>K</given-names></string-name>, <string-name><surname>Richman</surname> <given-names>D</given-names></string-name>, <string-name><surname>Little</surname> <given-names>S.</given-names></string-name> <year>2010</year>. <article-title>The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection</article-title>. <source>J Infect Dis</source> <volume>201</volume>:<fpage>1298</fpage>&#x2013;<lpage>1302</lpage>.</mixed-citation></ref>
<ref id="c59"><label>59.</label><mixed-citation publication-type="journal"><string-name><surname>Okafo</surname> <given-names>G</given-names></string-name>, <string-name><surname>Prevedel</surname> <given-names>L</given-names></string-name>, <string-name><surname>Eugenin</surname> <given-names>E.</given-names></string-name> <year>2017</year>. <article-title>Tunneling nanotubes (TNT) mediate long-range gap junctional communication: Implications for HIV cell to cell spread</article-title>. <source>Sci Rep</source> <volume>7</volume>:<issue>16660</issue>.</mixed-citation></ref>
<ref id="c60"><label>60.</label><mixed-citation publication-type="journal"><string-name><surname>Fouchier</surname> <given-names>RA</given-names></string-name>, <string-name><surname>Meyaard</surname> <given-names>L</given-names></string-name>, <string-name><surname>Brouwer</surname> <given-names>M</given-names></string-name>, <string-name><surname>Hovenkamp</surname> <given-names>E</given-names></string-name>, <string-name><surname>Schuitemaker</surname> <given-names>H.</given-names></string-name> <year>1996</year>. <article-title>Broader tropism and higher cytopathicity for CD4&#x002B; T cells of a syncytium-inducing compared to a non-syncytium-inducing HIV-1 isolate as a mechanism for accelerated CD4&#x002B; T cell decline in vivo</article-title>. <source>Virology</source> <volume>219</volume>:<fpage>87</fpage>&#x2013;<lpage>95</lpage>.</mixed-citation></ref>
<ref id="c61"><label>61.</label><mixed-citation publication-type="journal"><string-name><surname>Pope</surname> <given-names>M.</given-names></string-name> <year>1999</year>. <article-title>Mucosal dendritic cells and immunodeficiency viruses</article-title>. <source>J Infect Dis 179 Suppl</source> <volume>3</volume>:<fpage>S427</fpage>&#x2013;<lpage>430</lpage>.</mixed-citation></ref>
<ref id="c62"><label>62.</label><mixed-citation publication-type="journal"><string-name><surname>Kolson</surname> <given-names>DL</given-names></string-name>, <string-name><surname>Gonzalez-Scarano</surname> <given-names>F.</given-names></string-name> <year>2000</year>. <article-title>HIV and HIV dementia</article-title>. <source>J Clin Invest</source> <volume>106</volume>:<fpage>11</fpage>&#x2013;<lpage>13</lpage>.</mixed-citation></ref>
<ref id="c63"><label>63.</label><mixed-citation publication-type="journal"><string-name><surname>Symeonides</surname> <given-names>M</given-names></string-name>, <string-name><surname>Murooka</surname> <given-names>TT</given-names></string-name>, <string-name><surname>Bellfy</surname> <given-names>LN</given-names></string-name>, <string-name><surname>Roy</surname> <given-names>NH</given-names></string-name>, <string-name><surname>Mempel</surname> <given-names>TR</given-names></string-name>, <string-name><surname>Thali</surname> <given-names>M.</given-names></string-name> <year>2015</year>. <article-title>HIV-1-Induced Small T Cell Syncytia Can Transfer Virus Particles to Target Cells through Transient Contacts</article-title>. <source>Viruses</source> <volume>7</volume>:<fpage>6590</fpage>&#x2013;<lpage>6603</lpage>.</mixed-citation></ref>
<ref id="c64"><label>64.</label><mixed-citation publication-type="journal"><string-name><surname>Bracq</surname> <given-names>L</given-names></string-name>, <string-name><surname>Xie</surname> <given-names>M</given-names></string-name>, <string-name><surname>Lambele</surname> <given-names>M</given-names></string-name>, <string-name><surname>Vu</surname> <given-names>LT</given-names></string-name>, <string-name><surname>Matz</surname> <given-names>J</given-names></string-name>, <string-name><surname>Schmitt</surname> <given-names>A</given-names></string-name>, <string-name><surname>Delon</surname> <given-names>J</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>P</given-names></string-name>, <string-name><surname>Randriamampita</surname> <given-names>C</given-names></string-name>, <string-name><surname>Bouchet</surname> <given-names>J</given-names></string-name>, <string-name><surname>Benichou</surname> <given-names>S.</given-names></string-name> <year>2017</year>. <article-title>T cell-macrophage fusion triggers multinucleated giant cell formation for HIV-1 spreading</article-title>. <source>J Virol</source> doi:<pub-id pub-id-type="doi">10.1128/jvi.01237-17</pub-id>.</mixed-citation></ref>
<ref id="c65"><label>65.</label><mixed-citation publication-type="journal"><string-name><surname>Martinez-Mendez</surname> <given-names>D</given-names></string-name>, <string-name><surname>Rivera-Toledo</surname> <given-names>E</given-names></string-name>, <string-name><surname>Ortega</surname> <given-names>E</given-names></string-name>, <string-name><surname>Licona-Limon</surname> <given-names>I</given-names></string-name>, <string-name><surname>Huerta</surname> <given-names>L</given-names></string-name>. <year>2017</year>. <article-title>Monocyte-lymphocyte fusion induced by the HIV-1 envelope generates functional heterokaryons with an activated monocyte-like phenotype</article-title>. <source>Exp Cell Res</source> <volume>352</volume>:<fpage>9</fpage>&#x2013;<lpage>19</lpage>.</mixed-citation></ref>
<ref id="c66"><label>66.</label><mixed-citation publication-type="journal"><string-name><surname>Negi</surname> <given-names>N</given-names></string-name>, <string-name><surname>Das</surname> <given-names>BK.</given-names></string-name> <year>2017</year>. <article-title>CNS: Not an immunoprivilaged site anymore but a virtual secondary lymphoid organ</article-title>. <source>Int Rev Immunol</source> doi:<pub-id pub-id-type="doi">10.1080/08830185.2017.1357719:1-12</pub-id>.</mixed-citation></ref>
<ref id="c67"><label>67.</label><mixed-citation publication-type="journal"><string-name><surname>Calantone</surname> <given-names>N</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>F</given-names></string-name>, <string-name><surname>Klase</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Deleage</surname> <given-names>C</given-names></string-name>, <string-name><surname>Perkins</surname> <given-names>M</given-names></string-name>, <string-name><surname>Matsuda</surname> <given-names>K</given-names></string-name>, <string-name><surname>Thompson</surname> <given-names>EA</given-names></string-name>, <string-name><surname>Ortiz</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Vinton</surname> <given-names>CL</given-names></string-name>, <string-name><surname>Ourmanov</surname> <given-names>I</given-names></string-name>, <string-name><surname>Lore</surname> <given-names>K</given-names></string-name>, <string-name><surname>Douek</surname> <given-names>DC</given-names></string-name>, <string-name><surname>Estes</surname> <given-names>JD</given-names></string-name>, <string-name><surname>Hirsch</surname> <given-names>VM</given-names></string-name>, <string-name><surname>Brenchley</surname> <given-names>JM.</given-names></string-name> <year>2014</year>. <article-title>Tissue myeloid cells in SIV-infected primates acquire viral DNA through phagocytosis of infected T cells</article-title>. <source>Immunity</source> <volume>41</volume>:<fpage>493</fpage>&#x2013;<lpage>502</lpage>.</mixed-citation></ref>
<ref id="c68"><label>68.</label><mixed-citation publication-type="journal"><string-name><surname>Cong</surname> <given-names>L</given-names></string-name>, <string-name><surname>Ran</surname> <given-names>FA</given-names></string-name>, <string-name><surname>Cox</surname> <given-names>D</given-names></string-name>, <string-name><surname>Lin</surname> <given-names>S</given-names></string-name>, <string-name><surname>Barretto</surname> <given-names>R</given-names></string-name>, <string-name><surname>Habib</surname> <given-names>N</given-names></string-name>, <string-name><surname>Hsu</surname> <given-names>PD</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>X</given-names></string-name>, <string-name><surname>Jiang</surname> <given-names>W</given-names></string-name>, <string-name><surname>Marraffini</surname> <given-names>LA</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>F.</given-names></string-name> <year>2013</year>. <article-title>Multiplex genome engineering using CRISPR/Cas systems</article-title>. <source>Science</source> <volume>339</volume>:<fpage>819</fpage>&#x2013;<lpage>823</lpage>.</mixed-citation></ref>
<ref id="c69"><label>69.</label><mixed-citation publication-type="journal"><string-name><surname>Flynn</surname> <given-names>R</given-names></string-name>, <string-name><surname>Grundmann</surname> <given-names>A</given-names></string-name>, <string-name><surname>Renz</surname> <given-names>P</given-names></string-name>, <string-name><surname>Hanseler</surname> <given-names>W</given-names></string-name>, <string-name><surname>James</surname> <given-names>WS</given-names></string-name>, <string-name><surname>Cowley</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Moore</surname> <given-names>MD.</given-names></string-name> <year>2015</year>. <article-title>CRISPR-mediated genotypic and phenotypic correction of a chronic granulomatous disease mutation in human iPS cells</article-title>. <source>Exp Hematol</source> <volume>43</volume>:<fpage>838</fpage>&#x2013;<lpage>848 e833</lpage>.</mixed-citation></ref>
<ref id="c70"><label>70.</label><mixed-citation publication-type="journal"><string-name><surname>Sanjana</surname> <given-names>NE</given-names></string-name>, <string-name><surname>Shalem</surname> <given-names>O</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>F.</given-names></string-name> <year>2014</year>. <article-title>Improved vectors and genome-wide libraries for CRISPR screening</article-title>. <source>Nat Methods</source> <volume>11</volume>:<fpage>783</fpage>&#x2013;<lpage>784</lpage>.</mixed-citation></ref>
<ref id="c71"><label>71.</label><mixed-citation publication-type="journal"><string-name><surname>Brinkman</surname> <given-names>EK</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>T</given-names></string-name>, <string-name><surname>Amendola</surname> <given-names>M</given-names></string-name>, <string-name><surname>van Steensel</surname> <given-names>B</given-names></string-name>. <year>2014</year>. <article-title>Easy quantitative assessment of genome editing by sequence trace decomposition</article-title>. <source>Nucleic Acids Res</source> <volume>42</volume>:<fpage>e168</fpage>.</mixed-citation></ref>
<ref id="c72"><label>72.</label><mixed-citation publication-type="journal"><string-name><surname>Rhodes</surname> <given-names>T</given-names></string-name>, <string-name><surname>Wargo</surname> <given-names>H</given-names></string-name>, <string-name><surname>Hu</surname> <given-names>WS.</given-names></string-name> <year>2003</year>. <article-title>High rates of human immunodeficiency virus type 1 recombination: near-random segregation of markers one kilobase apart in one round of viral replication</article-title>. <source>J Virol</source> <volume>77</volume>:<fpage>11193</fpage>&#x2013;<lpage>11200</lpage>.</mixed-citation></ref>
<ref id="c73"><label>73.</label><mixed-citation publication-type="journal"><string-name><surname>He</surname> <given-names>J</given-names></string-name>, <string-name><surname>Choe</surname> <given-names>S</given-names></string-name>, <string-name><surname>Walker</surname> <given-names>R</given-names></string-name>, <string-name><surname>Di Marzio</surname> <given-names>P</given-names></string-name>, <string-name><surname>Morgan</surname> <given-names>DO</given-names></string-name>, <string-name><surname>Landau</surname> <given-names>NR.</given-names></string-name> <year>1995</year>. <article-title>Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity</article-title>. <source>J Virol</source> <volume>69</volume>:<fpage>6705</fpage>&#x2013;<lpage>6711</lpage>.</mixed-citation></ref>
<ref id="c74"><label>74.</label><mixed-citation publication-type="journal"><string-name><surname>Edmonds</surname> <given-names>TG</given-names></string-name>, <string-name><surname>Ding</surname> <given-names>H</given-names></string-name>, <string-name><surname>Yuan</surname> <given-names>X</given-names></string-name>, <string-name><surname>Wei</surname> <given-names>Q</given-names></string-name>, <string-name><surname>Smith</surname> <given-names>KS</given-names></string-name>, <string-name><surname>Conway</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Wieczorek</surname> <given-names>L</given-names></string-name>, <string-name><surname>Brown</surname> <given-names>B</given-names></string-name>, <string-name><surname>Polonis</surname> <given-names>V</given-names></string-name>, <string-name><surname>West</surname> <given-names>JT</given-names></string-name>, <string-name><surname>Montefiori</surname> <given-names>DC</given-names></string-name>, <string-name><surname>Kappes</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Ochsenbauer</surname> <given-names>C.</given-names></string-name> <year>2010</year>. <article-title>Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC</article-title>. <source>Virology</source> <volume>408</volume>:<fpage>1</fpage>&#x2013;<lpage>13</lpage>.</mixed-citation></ref>
<ref id="c75"><label>75.</label><mixed-citation publication-type="journal"><string-name><surname>Levy</surname> <given-names>DN</given-names></string-name>, <string-name><surname>Aldrovandi</surname> <given-names>GM</given-names></string-name>, <string-name><surname>Kutsch</surname> <given-names>O</given-names></string-name>, <string-name><surname>Shaw</surname> <given-names>GM.</given-names></string-name> <year>2004</year>. <article-title>Dynamics of HIV-1 recombination in its natural target cells</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>101</volume>:<fpage>4204</fpage>&#x2013;<lpage>4209</lpage>.</mixed-citation></ref>
<ref id="c76"><label>76.</label><mixed-citation publication-type="journal"><string-name><surname>Pornillos</surname> <given-names>O</given-names></string-name>, <string-name><surname>Ganser-Pornillos</surname> <given-names>BK</given-names></string-name>, <string-name><surname>Yeager</surname> <given-names>M.</given-names></string-name> <year>2011</year>. <article-title>Atomic-level modelling of the HIV capsid</article-title>. <source>Nature</source> <volume>469</volume>:<fpage>424</fpage>&#x2013;<lpage>427</lpage>.
</mixed-citation></ref>
</ref-list>
</back>
</article>
